The lymphocyte homing receptor CD44 , first described in 1983 ( REF . 1 ) , is expressed as a wide variety of isoforms in many cells . It attracted considerable interest when it was discovered that expression of a variant isoform of CD44 ( CD44v ) induced a metastatic phenotype in locally growing tumour cells 2 . There is now ample evi - dence for the importance of CD44 expression in the progression of many tumour types 3 , as well as for its expression on cancer - initiating cells ( CICs ; also known as cancer stem cells ) 4 . CICs have been defined as a selected population of tumour cells that grow on serial transplantation in xenogeneic models . These assays revealed that CICs can self - renew , and that tumours derived from purified CICs recapitulate the heterogeneous phenotype of the parental tumour , reflecting the differentiation ca pacity of CICs 5 – 7 . CICs , like stem cells , are highly resistant to apoptosis and are thought to be essential for metastasis formation after prolonged dormancy 6 . Distinct from stem cells , CICs might not be genetically sta ble 8 and can be hetero - geneous 9 , which is in line with their disputed and not mutually exclusive origin from adult stem cells ( ASCs ) and oncogenic transformed committed progenitors or their production as a result of cell fusion , in which bone marrow - derived cells may contribute , particularly in cancer arising as a result of infection 10 . As CICs frequently express CD44 , this raises the question : what does CD44 do for these cells ? As the asso - ciation of CICs with CD44 expression is a fairly recent discovery , most of the information regarding the func - tion of CD44 is provided by ASCs 11 and tumour cells in general rather than by CICs . In this Review I re - evaluate the major activities of this multifaceted and multifunctional molecule using infor - mation from many different cell types and ask whether these functions might explain why CICs express CD44 . The structure of CD44 CD44 was cloned in 1989 and identified as a member of the cartilage link protein family 12 , 13 . CD44 is an impor - tant receptor that binds hyaluronan ( HA ) 14 . CD44 glyco - proteins , which are encoded by a single gene 15 , vary in size owing to N - glycosylation and O - glycosylation 12 , 13 and the insertion of alternatively spliced exon prod ucts in the extracellular domains of the molecule 15 . The smallest , standard or haematopoietic isoform ( CD44s ) is present on the membrane of most vertebrate cells 3 . CD44 has seven extracellular domains , a transmembrane domain and a cytoplasmic domain 16 . The cytoplasmic domain can be encoded by exons 9 or 10 ( REF . 17 ) . Between domains 5 and 6 , up to ten variant exon products can be inserted by alternative splicing 15 ( FIG . 1 ) . The five amino - terminal exons encode a globular struc - ture that contains two binding domains , the link do main ( amino acids 32 – 132 ) and a basic motif outside the link domain ( amino acids 150 – 158 ) to which HA binds 14 , 18 . Binding sites within the globular structure for collagen , laminin 19 , fibronectin 20 and cell surface receptors such as CD62E and CD62L 21 have also been characterized . CD44 has two active binding sites for other gly cosaminoglycans ( GAGs ) 22 . Four conserved cysteines are important for the stability of the extra cellular domain , and two cysteines in the flanking region are important for correct folding of the link domain 23 . Between the N - terminal globular Department of Tumour Cell Biology , University Hospital of Surgery and German Cancer Research Centre , D69120 Heidelberg , Germany . e‑mail : margot . zoeller @ uni‑ heidelberg . de doi : 10 . 1038 / nrc3023 Published online 10 March 2011 Alternative splicing A key mechanism that accounts for gene expression diversity . Splicing is tightly regulated by a range of RNA and protein factors and RNA sequence elements that function in a cooperative manner . Link domain Named according to considerable homologies with the cartilage link protein and the proteoglycan core protein . CD44 : can a cancer - initiating cell profit from an abundantly expressed molecule ? Margot Zöller Abstract | Can an abundantly expressed molecule be a reliable marker for the cancer - initi ating cells ( CICs ; also known as cancer stem cells ) , which constitute the minority of cells within the mass of a tumour ? CD44 has been implicated as a CIC marker in several malignancies of haematopoietic and epithelial origin . Is this a fortuitous coincidence owing to the widespread expression of the molecule or is CD44 expression advantageous as it fulfils some of the special properties that are displayed by CICs , such as self - renewal , niche preparation , epithelial – mesenchymal transition and resistance to apoptosis ? R E V I E W S 254 | APRIL 2011 | VOLUME 11 www . nature . com / reviews / cancer © 2011 Macmillan Publishers Limited . All rights reserved SRC family Cytoplasmic tyrosine kinases , which are controlled by multiple mem brane receptors and which signal to various downstream effectors . ERM proteins Mediate actin – membrane linkage and regulate signalling molecules . Bmi1 Member of the Polycomb group of transcriptional repressors that epigenetically modify chromatin and participate in the establishment and maintenance of cell fates . These proteins have important roles in both stem cell self - renewal and cancer development . ATP - binding cassette ( ABC ) transporters Can pump a wide variety of endogenous and exogenous compounds out of cells . They are widely expressed in stem cells and CICs and confer the side population phenotype . domain and the transmembrane domain there is a stretch of 46 amino acids that form a stalk - like structure 24 . This structure contains putative proteolytic cleavage sites and is heavily glycosylated 25 . This stretch can be enlarged by the insertion of variable exon products 26 . O - glycosylation and the cytoplas mic tail of CD44 can affect membrane subdomain localization and so influence the interaction of CD44 with HA 27 . Unlike CD44s , CD44v is only expressed on some epi - thelial cells , during embryonic development , lymphocyte maturation and activation , and in several types of car - cinoma 28 . The CD44v segments contain some specific post - translational modifications that include a heparan sulphate site in exon v3 , which binds heparin - binding proteins such as fibroblast growth factor 2 ( FGF2 ) 29 . CD44v6 contains a binding site for hepatocyte growth factor ( HGF ) and vascular en dothelial growth factor ( VEGF ) 30 , 31 . Not all CD44 - positive cells bind HA , but HA binding can be induced by CD44 crosslinking , which results in conformational changes or a redistribution of CD44 in the cell membrane 32 . The transmembrane region con - tributes to CD44 oligomerization 33 and incorporation in glycolipid - enriched microdomains ( GEMs ) . The GEM association of CD44 , which varies between different cell types and their activation state 34 , is particularly important in CD44 - mediated signal transduction , as the inner side of these membrane microdomains harbours adaptor and signal - transducing molecules such as members of the SRC family , some of which are constitutively associated with CD44 ( REF . 35 ) . The cytoplasmic tail and its associations with partner molecules are crucial for the accessory functions of CD44 in signal transduction and its subdomain localization during cell migration . Cytoplasmic partner molecules of CD44 are the cytoskeletal proteins ankyrin , and ezrin , radixin and moesin ( ERM proteins ) . Ankyrin mediates contact with spectrin and is involved in HA - dependent cell adhesion and motility 36 . ERM proteins are engaged in the regulation of cell migration , cell shape and protein re sorting in the plasma membrane 37 . The N terminus of activated ERM proteins binds to a motif be tween the transmembrane region and the ankyrin - binding site , and their carboxyl terminus binds to filamen tous actin ( F - actin ) , thus linking CD44 to the actin cyto skeleton 38 . Merlin , an additional member of the ERM family lacks the C - terminal actin - binding domain , but might be involved in stabilizing the junc tional – cortical actin interface through its N - terminal domain 39 . The binding of CD44 to cytoskeletal linker proteins influences signal - ling pathways downstream of CD44 , thus initiating and expanding the range of CD44 - mediated functions . CD44 is a stem cell and CIC marker The idea that stem cells could be important in the aeti - ology of cancer dates back more than a century , when Virchow proposed that cancer arises from embryonic - like cells 40 . Evidence for a minor popula tion of human acute myeloid leukaemia ( AML ) cells that could trans - plant leukaemias between im munocompromised mice established the presence of leukaemia - initiating cells ( LICs ) 41 . Deletion of Bmi1 , which is important for hae - matopoietic stem cell ( HSC ) self - renewal , prevented leukaemia recurrence 42 . Since these influential find - ings , CICs have been identified by serial xenogeneic transplantation in several types of solid tumour 5 . Notably , tumour growth in xenogeneic models has provided additional , important information . In the xenogeneic system higher take rates are observed when CICs are suspended in Matrigel or co - injected with normal stroma cells 43 , 44 . These findings indi - cate that CICs communicate with their sur roundings and that stromal elements might have a crucial role in CIC maintenance . In vitro enrichment of CICs has been achieved by growth as cellular spheres 45 and expression of ATP - binding cassette ( ABC ) transporters 5 , 46 . However , over recent years the expression of cell surface markers that correlate with CIC - like characteristics has been used to identify CIC populations . The most frequent markers shared by CICs of different origins are CD20 , CD24 , CD34 , CD44 , CD90 , CD117 , CD133 , aldehyde dehydrogenase ( ALDH ) , nestin , the β1 integrin chain and EpCAM , and CD44 is the most frequently observed CIC marker 47 ( Supplementary information S1 , S2 ( tables ) ) . It should be mentioned that , although the particular importance of CD44v in tumour progression has been demon - strated in many tumours 3 , most reports on the defini - tion of CD44 as a CIC marker are based on isolation by panCD44 - specific antibodies that recognize CD44s , as well as CD44v molecules . Thus , CD44v expression in CICs remains unexplored . At a glance • CD44 , the major hyaluronan ( HA ) receptor , makes abundant use of alternative splicing and can be located in glycolipid - enriched microdomains ( GEMs ) . The extracellular and the cytoplasmic domains can associate with a large array of molecules . • Cancer - initi ating cells ( CICs ; also known as cancer stem cells ) constitute a minor population of cells within a tumour , but are frequently essential for tumour mainte nance and progression . CICs can be enriched by so - called CIC markers , the most common of which is CD44 . • CD44 can contribute to the activation of stem cell regulatory genes and can be a target of these genes , but there is , at present , no compelling evidence that CD44 has a central role in self - renewal and maintenance of pluripotency . • CD44 binding to HA has an important role in haematopoietic stem cells ( HSCs ) and leukaemia - initiating cells ( LICs ) and probably CIC homing and adhesion . HA binding - induced changes in CD44 membrane localization and conformation trigger the association and activation of multiple signal transduction molecules and of proteases , which supports migration . • CD44 accounts for the homing and settling of adult stem cells ( ASCs ) , as well as metastasizing tumour cells and CICs in the niche , is actively involved in niche assembly through its effect on HA secretion and degradation , mainly owing to its activity as a catcher of chemokines , growth factors and matrix - degrading enzymes . • The HA – CD44 and HA – CD44v interactions have a central role in receptor tyrosine kinase ( RTK ) - induced activation of anti - apoptotic pathways and actively promote tumour cell and possibly CIC survival through their associations with multidrug resistance genes . Im portantly , activation of signalling pathways initiated by the tumour matrix could be inhibited by HA degradation , by competition with small HA fragments , by CD44 blockade or by CD44 knockdown , whereas a blockade of an individual RTK did not recapitulate all of the effects observed on inhibition of CD44 – HA binding . R E V I E W S NATURE REVIEWS | CANCER VOLUME 11 | APRIL 2011 | 255 © 2011 Macmillan Publishers Limited . All rights reserved (cid:48)(cid:67)(cid:86)(cid:87)(cid:84)(cid:71)(cid:2)(cid:52)(cid:71)(cid:88)(cid:75)(cid:71)(cid:89)(cid:85)(cid:2) (cid:94) (cid:2)(cid:37)(cid:67)(cid:80)(cid:69)(cid:71)(cid:84) (cid:56)(cid:67)(cid:84)(cid:75)(cid:67)(cid:80)(cid:86)(cid:75)(cid:85)(cid:81)(cid:72)(cid:81)(cid:84)(cid:79)(cid:85)(cid:2) (cid:54)(cid:84)(cid:67)(cid:80)(cid:85)(cid:79)(cid:71)(cid:79)(cid:68)(cid:84)(cid:67)(cid:80)(cid:71)(cid:2)(cid:70)(cid:81)(cid:79)(cid:67)(cid:75)(cid:80)(cid:28)(cid:2)(cid:67)(cid:79)(cid:75)(cid:80)(cid:81)(cid:2) (cid:67)(cid:69)(cid:75)(cid:70)(cid:85)(cid:2)(cid:20)(cid:24)(cid:27)(cid:115)(cid:20)(cid:26)(cid:27)(cid:2) (cid:39)(cid:52)(cid:47)(cid:15)(cid:68)(cid:75)(cid:80)(cid:70)(cid:75)(cid:80)(cid:73)(cid:2)(cid:70)(cid:81)(cid:79)(cid:67)(cid:75)(cid:80)(cid:28)(cid:2)(cid:67)(cid:79)(cid:75)(cid:80)(cid:81)(cid:2)(cid:67)(cid:69)(cid:75)(cid:70)(cid:85)(cid:2)(cid:20)(cid:27)(cid:20)(cid:115)(cid:21)(cid:18)(cid:18)(cid:2) (cid:35)(cid:80)(cid:77)(cid:91)(cid:84)(cid:75)(cid:80)(cid:15)(cid:68)(cid:75)(cid:80)(cid:70)(cid:75)(cid:80)(cid:73)(cid:2)(cid:70)(cid:81)(cid:79)(cid:67)(cid:75)(cid:80)(cid:28)(cid:2)(cid:67)(cid:79)(cid:75)(cid:80)(cid:81)(cid:2)(cid:67)(cid:69)(cid:75)(cid:70)(cid:85)(cid:2)(cid:21)(cid:18)(cid:22)(cid:115)(cid:21)(cid:19)(cid:26)(cid:2) (cid:46)(cid:75)(cid:80)(cid:77)(cid:2)(cid:70)(cid:81)(cid:79)(cid:67)(cid:75)(cid:80)(cid:28)(cid:2)(cid:67)(cid:79)(cid:75)(cid:80)(cid:81)(cid:2)(cid:67)(cid:69)(cid:75)(cid:70)(cid:85)(cid:2)(cid:21)(cid:20)(cid:115)(cid:19)(cid:21)(cid:20)(cid:2) (cid:56)(cid:67)(cid:84)(cid:75)(cid:67)(cid:80)(cid:86)(cid:2)(cid:75)(cid:85)(cid:81)(cid:72)(cid:81)(cid:84)(cid:79)(cid:85)(cid:10)(cid:79)(cid:87)(cid:78)(cid:86)(cid:75)(cid:82)(cid:78)(cid:71)(cid:2)(cid:69)(cid:81)(cid:79)(cid:68)(cid:75)(cid:80)(cid:67)(cid:86)(cid:75)(cid:81)(cid:80)(cid:85)(cid:11)(cid:2) (cid:53)(cid:86)(cid:67)(cid:78)(cid:77)(cid:2)(cid:70)(cid:81)(cid:79)(cid:67)(cid:75)(cid:80) (cid:67) (cid:68) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:37)(cid:38)(cid:22)(cid:22)(cid:85)(cid:53)(cid:86)(cid:67)(cid:80)(cid:70)(cid:67)(cid:84)(cid:70)(cid:2)(cid:75)(cid:85)(cid:81)(cid:72)(cid:81)(cid:84)(cid:79)(cid:2) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:26)(cid:115)(cid:88)(cid:19)(cid:18)(cid:39)(cid:82)(cid:75)(cid:86)(cid:74)(cid:71)(cid:78)(cid:75)(cid:67)(cid:78)(cid:2)(cid:75)(cid:85)(cid:81)(cid:72)(cid:81)(cid:84)(cid:79)(cid:2) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:21)(cid:115)(cid:88)(cid:19)(cid:18)(cid:45)(cid:71)(cid:84)(cid:67)(cid:86)(cid:75)(cid:80)(cid:81)(cid:69)(cid:91)(cid:86)(cid:71)(cid:2)(cid:75)(cid:85)(cid:81)(cid:72)(cid:81)(cid:84)(cid:79)(cid:2) (cid:39)(cid:90)(cid:81)(cid:80)(cid:2) (cid:53)(cid:19)(cid:2) (cid:53)(cid:20)(cid:2) (cid:53)(cid:21)(cid:2) (cid:53)(cid:22)(cid:2) (cid:53)(cid:23)(cid:2) (cid:53)(cid:24)(cid:2) (cid:53)(cid:25)(cid:2) (cid:53)(cid:26)(cid:2) (cid:53)(cid:27)(cid:2) (cid:53)(cid:19)(cid:18)(cid:2) (cid:56)(cid:19)(cid:2) (cid:56)(cid:20)(cid:2) (cid:56)(cid:21)(cid:2) (cid:56)(cid:22)(cid:2) (cid:56)(cid:23)(cid:2) (cid:56)(cid:24)(cid:2) (cid:56)(cid:25)(cid:2) (cid:56)(cid:26)(cid:2) (cid:56)(cid:27)(cid:2) (cid:56)(cid:19)(cid:18)(cid:2) (cid:19) (cid:20) (cid:21) (cid:22) (cid:23) (cid:24) (cid:25) (cid:26) (cid:27) (cid:19)(cid:18) (cid:19)(cid:19) (cid:19)(cid:20) (cid:19)(cid:21) (cid:19)(cid:22) (cid:19)(cid:23) (cid:19)(cid:24) (cid:19)(cid:25) (cid:19)(cid:26) (cid:19)(cid:27) (cid:20)(cid:18) (cid:39)(cid:90)(cid:86)(cid:84)(cid:67)(cid:69)(cid:71)(cid:78)(cid:78)(cid:87)(cid:78)(cid:67)(cid:84)(cid:2) (cid:54)(cid:47)(cid:2) (cid:37)(cid:50)(cid:2) (cid:39)(cid:90)(cid:86)(cid:84)(cid:67)(cid:69)(cid:71)(cid:78)(cid:78)(cid:87)(cid:78)(cid:67)(cid:84)(cid:2) (cid:54)(cid:47)(cid:2)(cid:37)(cid:50)(cid:2) (cid:37)(cid:38)(cid:22)(cid:22)(cid:85)(cid:2) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:2) (cid:69) Protein kinase C e ( PKC e ) Several isoforms of this enzyme mediate serine and threonine phosphoryla tion in many different protein substrates thus propagating various signal transduction pathways leading to transcription factor activation . CD44 , stem cell master genes and epigenetics Embryonic stem ( ES ) cells are characterized by the expression of a set of transcription factors 48 – 50 , as well as by distinct chromatin organization and epigenetic signa - tures that govern their intrinsic ability to self - renew and differentiate into multiple lineages 51 . ASCs , CICs and ES cells express OCT4 , NANOG and MYC 11 , 52 , and several papers have shown that the signalling pathways Notch , Wnt and Hedgehog , which are important for shaping tis - sue structure , cell fate and identity 53 , are also important for stem cell function . CD44 does not seem to belong to the group of genes , such as OCT4 and NANOG , that are central for main - taining stem cell characteristics . Nonetheless , two con - nections between CD44 and genes that regulate stem cell characteristics have been described . First , CD44 is a target of the Wnt pathway . Patients with adeno - matous polyposis coli ( APC ) tumour suppressor gene mutations develop hundreds of colorectal polyps 54 . Loss of APC function leads to the constitu tive activa - tion of β - catenin , a constituent of the Wnt signalling pathway . CD44s and CD44v6 expres sion is restricted to the intestinal crypts in non - transformed tissue , but both CD44 isoforms are strongly overexpressed in dys - plastic crypts and adenomas in humans and mice with mutant APC 55 . In mice with mutated TCF4 , a transcrip - tion factor that is activated by β - catenin , CD44 is not expressed in the epithelium of the small intestine , which is accompanied by a loss of intestinal stem cells 55 . These authors suggested that CD44 expression in intestinal crypts is part of a genetic programme that is control - led by the Wnt signalling pathway . Second , HA – CD44 binding promotes protein kinase C ε ( PKC ε ) activation and this increases NANOG phosphorylation and translo - cation to the nucleus . Here , it associates with Drosha and an RNA helicase , p68 , leading to the transcrip - tion of the oncogenic microRNA ( miRNA ) miR - 21 and a reduction in the expres sion of the tumour suppres - sor programmed cell death 4 . These events initiate the upregulation of the in hibitor of apoptosis ( IAP ) pro - teins and multidrug - resistant protein 1 ( MDR1 ; also known as P - glycoprotein ) 56 . CD44 , in turn , associates with and stabilizes MDR1 expression 57 . This could be one mechanism through which CD44 contributes to stem cell resistance to chemotherapy , as MDR1 exports several drugs from cells . By contrast , pro - metastatic miR - 373 – 520c downregulates CD44 ( REF . 58 ) , indicat - ing that the regulation of CD44 expression by miRNAs might be context - dependent . Finally , stimulated by early reports on the metastasis - promoting activity of CD44v isoforms 2 , 3 , several stud - ies addressed aberrant and alternative splicing in cancer on a gene by gene basis . There is evi dence that expression of certain cancer - specific variants cor - relates with tumour progression . In this list , which includes many tumour suppressor genes , CD44 is the most frequently affected 59 . However , although mutations in splicing elements have been observed in several oncogenes , no mutations have been found in cis - acting splice elements of CD44 ( REF . 60 ) . Thus , whether the alternative splicing of CD44 in cancers is the result of genetic or epigenetic changes remains to be elucidated . Stem cells , adhesion , homing and migration Shared features between CICs and stem cells are fre - quently linked to secondary events such as interac - tion with a niche , the process of epithelial – mesenchymal transition ( EMT ) 61 , and migration and apoptosis resistance , which have all been associated with CD44 ( REFS 62 , 63 ) . Cell adhesion is indispensible for the development of multicellular organisms and stem cell adhesion and migration is essential in embryogenesis and tissue remodelling 64 . Thus , adhesive and motility - promoting activities of CD44 in stem cells might well be important for CICs . Figure 1 | CD44 gene and protein structure . a | CD44 consists of several exons , some of which are constant region exons that are used in every CD44 mRNA and protein ( green bars ) and others are variant exons ( red bars ) that are used in the CD44 variant proteins and are selected by alternative splicing . b | Examples of alternatively spliced CD44 proteins . c | The CD44 protein is composed of an extracellular link do main , a stalk - like region in the extracellular domain close to the transmembrane region , where the variant exon products ( red ) are inserted , the transmembrane region ( TM ) and the cytoplasmic tail ( CP ) . There are multiple sites for N - glycosylation ( brown circles ) and O - glycosylation ( orange circles ) and two active gly cosaminoglycan ( GAG ) - binding sites ( yellow circles ) , one located in the v3 exon product . The link module con tains the binding site for hyaluronan ( HA ) . The cytoplasmic tail has binding motifs for cytoskeletal linker pro teins , as well as for SRC kinases . ERM , ezrin , radixin and moesin ; S – S , disulphide bonds . R E V I E W S 256 | APRIL 2011 | VOLUME 11 www . nature . com / reviews / cancer © 2011 Macmillan Publishers Limited . All rights reserved MicroRNA ( miRNA ) A class of small non - coding RNA molecules that regulate gene expression at the post - transcriptional level . Epithelial – mesenchymal transition ( EMT ) An evo lutionary conserved developmental programme adopted by tumour cells , in which cells change from an epithelial to a mesenchymal phenotype . Extracellular matrix ( ECM ) Well - ordered complex network of glycoproteins and proteoglycans sur rounding cells and organizing tissue . It is essential for cell survival , migration and proliferation . Endosteal niche Arrangement of osteoblasts , osteoclasts , mesenchymal stem cells , reticular cells and probably endothelial cells at the inner site of the bone that serves for homing and activity of HSCs . Focal adhesion kinase ( FAK ) A non - receptor protein tyrosine kinase . FAK is a scaffold for or ganizing a network of signalling and cytoskeletal proteins . It is implicated in signalling pathways in volved in cell motility , proliferation and apoptosis . CD44 , adhesion and homing . HA , the major CD44 ligand 14 , is the most abundant component of the extra - cellular matrix ( ECM ) 65 . Indeed , HA binding initiates , or at least influences , most activities of CD44 ( REF . 66 ) . The importance of CD44 as an adhesion molecule has been amply demonstrated for HSCs and LICs 67 . In 1990 Miyake et al . de scribed that CD44 - specific antibodies prohibited the development of ‘cobblestone areas’ , clus - ters of early haematopoietic progenitor cells and non - adherent progenitors in murine long - term bone marrow cultures 68 . Adhesion of CD44 to its ligands induces upregulation of additional adhesion molecules , mostly integrins , that strengthen HSC adhesion 69 . Human and mouse HSCs synthesize HA 70 , and HA expression correlates with HSC migration to the en dosteal niche 71 . HSC homing can be blocked by CD44 - specific antibodies , soluble HA or treatment with hyaluronidase ( HYAL ) 72 . In addition , CXCL12 stimulates adhesion of progenitor cells through CD44 , demonstrating cross - talk between CD44 and CXCR4 signalling , which sug - gests a key role of HA and CD44 in CXCL12 - dependent transendothelial migration of HSCs and their anchorage in spe cific niches 71 ( FIG . 2a ) . CD44 also participates in LIC homing . In AML , CD44 is required for the transportation of LICs to the HSC niche , and CD44 - specific antibodies alter the fate of the LICs by inducing differentiation 73 . In a mouse model of chronic myeloid leukaemia ( CML ) , BCR – ABL1 - transduced pro - genitors from CD44 - mutant donors were defective in bone marrow homing , which resulted in decreased engraftment and impaired induction of a CML - like disease 74 . These studies provided additional evidence that LICs may be more dependent on CD44 for homing than HSCs 73 . Studies in a murine model confirmed that leukaemia cell homing and growth is retarded by a CD44 - specific antibody 75 . However , during experiments examining the reconstitution of the bone marrow , a panCD44 - specific antibody interfered with HSCs more efficiently than leu - kaemia cell homing to the bone marrow 75 . Displacement of HSCs from the niche by LICs might also be a conse - quence of LICs remodelling the niche so that it no longer serves the requirements of the HSCs 76 . A large - scale clinical study showed a lower cancer - related survival rate in Duke’s stage C and D colo rectal cancer with high HA staining intensity 77 , leading to the hypothesis that CD44 - mediated adhesion to HA is also a crucial factor in regulating solid tumour cell adhesion to the surrounding normal tissue 78 . CD44 , extravasation and migration . Metastasizing tumour cells , as well as haematopoietic cells , need to extravasate , which involves CD44 ( REF . 79 ) . In endothe - lial cells , pro - inflammatory cytokines stimulate CD44 expression and strengthen their binding to HA . This pro - motes the arrest of haematopoietic cells and tumour cells , which bind to HA that is captured by endothelial cells through CD44 ( REF . 80 ) . In addition , CD44v in par - ticular promotes the interaction with HA on endothe - lial cells and cell transmigration : CD44v is an important ligand for CD62P , which stabilizes CD62L - dependent rolling of immune and tumour cells 22 ( FIG . 2 ) . The migration of tumour cells , which is promoted by CD44 – HA binding , relies on binding - induced interac - tions of the CD44 cytoplasmic tail with the actin cytoskel - eton through ankyrin and ERM proteins 36 , 37 , and CD44 is thus guided to the leading edge of migrating cells 81 ( FIG . 2b – d ) . Thus , melanoma cells expressing CD44 with a truncated cytoplasmic tail retain their HA - binding capac - ity , but lose the capacity to migrate on HA 82 . The underly - ing molecular mechanisms are partly well explored . For example , one of the central events in CD44 - mediated cytoskeletal reorganization seems to be RAC1 activa - tion . Lamellipodia formation in a mouse mammary epithelial cell line on HA - coated plates was inhibited by a CD44 - blocking antibody , but also by transfection of a dominant - negative mutant form of RAC1 ( REF . 83 ) . VAV1 and VAV2 , phosphotyrosine - dependent guanine exchange factors ( GEFs ) of the Rho family of GTPases 84 , are upstream regulators of RAC1 . Vav phosphorylation is mediated by SRC family kinases 84 . Thus , CD44 - associated SRC 83 could well be a starting point , through which CD44 – HA crosslinking initiates cytoskeleton reorgani - zation . Another mediator of CD44 signalling is RHOA . The RHOA - specific GEF p115RHOGEF , which interacts with CD44 , regulates HA - mediated CD44 signalling through the serine / threonine Rho kinase ( ROK ) , which is a downstream target of RHOA . ROK phosphorylates CD44 , leading to enhanced ankyrin binding 85 ( FIG . 2b ) . Through activated ROK , the HA – CD44 interaction also leads to phosphorylation of an Na + / H + exchanger , which supports ECM degradation and invasion by cre - ating an acidic environment with activation of HYAL2 and cathepsin B . A recent review on the multiple path - ways through which the HA – CD44 interaction activates RhoGTPases has shown the contribution of HA – CD44 to tumour cell - specific transcriptional activity , adhesion , migration , invasion and survival , all of which are essen - tially required for metastasis formation 86 . Furthermore , through the association of CD44 with integrins , CD44 gains access to focal adhesion kinase ( FAK ) , and integrins gain access to SRC kinases and ERM proteins , so that the integrin – paxillin association becomes weakened and the GEM - integrated CD44 – ezrin – integrin – FAK complex moves towards the leading edge of the cell , promoting cell migration 87 ( FIG . 2b ) . Rapid activation of membrane - integrated proteases by CD44 – HA binding enables the interaction between cell surface CD44 and HA to be dynamically regulated during migration , with cleavage of CD44 triggered by distinct stimuli . The pres - ence of CD44 at the leading edge results in its cleavage by a disintegrin and metalloproteinase domain ( ADAM ) proteins and matrix metalloproteinase 14 ( MMP14 ) 88 . Ca 2 + influx can also induce CD44 ectodomain shedding by ADAM10 , and Ca 2 + triggers the dissociation of pro - ADAM10 from calmodulin and ADAM10 activation ( FIG . 2c ) . In addition , PKC and Rac activation trigger the activation of ADAM17 , which localizes with CD44 at Rac - regulated membrane ruffles and contributes to the turnover of adhesion in the leading edge of migrat - ing cells 89 , 90 ( FIG . 2c ) . Inhibition of CD44 cleavage leads to the inhibition of tumour cell migration on HA 91 and might , therefore , also have an effect on CIC migration . R E V I E W S NATURE REVIEWS | CANCER VOLUME 11 | APRIL 2011 | 257 © 2011 Macmillan Publishers Limited . All rights reserved (cid:48)(cid:67)(cid:86)(cid:87)(cid:84)(cid:71)(cid:2)(cid:52)(cid:71)(cid:88)(cid:75)(cid:71)(cid:89)(cid:85)(cid:2) (cid:94) (cid:2)(cid:37)(cid:67)(cid:80)(cid:69)(cid:71)(cid:84) (cid:37)(cid:67) (cid:20)(cid:13) (cid:2) (cid:40)(cid:35)(cid:45)(cid:2) (cid:52)(cid:49)(cid:45)(cid:2) (cid:52)(cid:42)(cid:49)(cid:35) (cid:52)(cid:74)(cid:81)(cid:41)(cid:39)(cid:40) (cid:50)(cid:45)(cid:37)(cid:2) (cid:52)(cid:67)(cid:69) (cid:50)(cid:45)(cid:35)(cid:2) (cid:50)(cid:67)(cid:90)(cid:75)(cid:78)(cid:78)(cid:80)(cid:2) (cid:37)(cid:35)(cid:47)(cid:2) (cid:43)(cid:50)(cid:21) (cid:37)(cid:38)(cid:22)(cid:22)(cid:2)(cid:43)(cid:37)(cid:38)(cid:2) (cid:50)(cid:84)(cid:71)(cid:85)(cid:71)(cid:80)(cid:75)(cid:78)(cid:75)(cid:80)(cid:2)(cid:20)(cid:115) γ (cid:15)(cid:85)(cid:71)(cid:69)(cid:84)(cid:71)(cid:86)(cid:67)(cid:85)(cid:71)(cid:69)(cid:81)(cid:79)(cid:82)(cid:78)(cid:71)(cid:90)(cid:2)(cid:2) (cid:54)(cid:41)(cid:40) β (cid:37)(cid:54)(cid:53)(cid:41)(cid:2) (cid:39)(cid:37)(cid:47) (cid:37)(cid:36)(cid:50)(cid:2) (cid:36)(cid:81)(cid:80)(cid:71)(cid:2)(cid:84)(cid:71)(cid:85)(cid:81)(cid:84)(cid:82)(cid:86)(cid:75)(cid:81)(cid:80)(cid:2) (cid:47)(cid:47)(cid:50)(cid:27)(cid:2) (cid:47)(cid:47)(cid:50)(cid:27)(cid:2) (cid:47)(cid:47)(cid:50)(cid:20)(cid:2) (cid:50)(cid:84)(cid:81)(cid:47)(cid:47)(cid:50)(cid:20)(cid:2) (cid:47)(cid:47)(cid:50)(cid:19)(cid:22)(cid:2) (cid:39)(cid:80)(cid:70)(cid:81)(cid:85)(cid:86)(cid:71)(cid:67)(cid:78)(cid:2)(cid:80)(cid:75)(cid:69)(cid:74)(cid:71)(cid:2) (cid:37)(cid:52)(cid:37)(cid:58)(cid:22)(cid:2) α (cid:22) β (cid:19) (cid:37)(cid:38)(cid:22)(cid:22)(cid:2) (cid:42)(cid:53)(cid:37)(cid:2) (cid:46)(cid:43)(cid:37)(cid:2) (cid:37)(cid:58)(cid:37)(cid:46)(cid:19)(cid:20)(cid:2) (cid:37)(cid:58)(cid:37)(cid:46)(cid:19)(cid:20)(cid:2) (cid:39)(cid:52)(cid:47)(cid:2) (cid:35)(cid:69)(cid:86)(cid:75)(cid:80)(cid:2) (cid:35)(cid:80)(cid:77)(cid:91)(cid:84)(cid:75)(cid:80)(cid:2) (cid:54)(cid:87)(cid:79)(cid:81)(cid:87)(cid:84)(cid:2)(cid:69)(cid:71)(cid:78)(cid:78) (cid:50)(cid:84)(cid:81)(cid:35)(cid:38)(cid:35)(cid:47)(cid:19)(cid:18)(cid:2) (cid:35)(cid:70)(cid:74)(cid:71)(cid:84)(cid:71)(cid:80)(cid:86)(cid:78)(cid:71)(cid:87)(cid:77)(cid:81)(cid:69)(cid:91)(cid:86)(cid:71)(cid:2) (cid:37)(cid:43)(cid:37)(cid:2) (cid:50)(cid:78)(cid:67)(cid:86)(cid:71)(cid:78)(cid:71)(cid:86)(cid:2) (cid:39)(cid:80)(cid:70)(cid:81)(cid:86)(cid:74)(cid:71)(cid:78)(cid:75)(cid:67)(cid:78)(cid:2)(cid:69)(cid:71)(cid:78)(cid:78)(cid:2) (cid:39)(cid:90)(cid:86)(cid:84)(cid:67)(cid:88)(cid:67)(cid:85)(cid:67)(cid:86)(cid:75)(cid:80)(cid:73)(cid:37)(cid:43)(cid:37)(cid:2) αβ (cid:2)(cid:75)(cid:80)(cid:86)(cid:71)(cid:73)(cid:84)(cid:75)(cid:80)(cid:2) (cid:35) (cid:38) (cid:35) (cid:47) (cid:19)(cid:25) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:24)(cid:2) (cid:53)(cid:52)(cid:37) (cid:50)(cid:46)(cid:37) γ (cid:50)(cid:2) (cid:67) (cid:68) (cid:69) (cid:70) (cid:71) (cid:37)(cid:38)(cid:24)(cid:20) (cid:114)(cid:2)(cid:47)(cid:47)(cid:50)(cid:20)(cid:2)(cid:114)(cid:2)(cid:47)(cid:47)(cid:50)(cid:27)(cid:2)(cid:114)(cid:2)(cid:87)(cid:50)(cid:35)(cid:52) (cid:114)(cid:2)(cid:37)(cid:54)(cid:53)(cid:41)(cid:2)(cid:114)(cid:2)(cid:47)(cid:47)(cid:50)(cid:27)(cid:2)(cid:2) Figure 2 | The engagement of CD44 in HSC and CIC homing and migration . a | Haematopoietic stem cells ( HSCs ) and leukaemia - initiating cells ( LICs ) home via CD44 in the hyaluronan ( HA ) - rich endosteal niche . This has been proved for HSCs and LICs via antibody blocking . Additional important factors for HSC and LIC homing are α 4 β 1 ( antibodies are used for HSC mobilization ) and CXCR4 , the receptor for CXCL12 , provided by cells of the endosteal niche . Both α 4 β 1 and CXCR4 are associated with CD44 , which strengthens HSC and LIC adhesion . b | Activation of several signal transduction pathways supports leading edge adhesion of CD44 and the turnover required for migration . All rely on the association of CD44 with actin via cy toskeletal linker proteins , as well as on the association of CD44 with several members of the family of SRC kinases , which is facilitated by localization in glycolipid - enriched microdomains ( GEMs ) . One of the adhesion - strengthening signalling pathways proceeds via the CD44 association - initiated activation of a Rho guanine exchange factor ( GEF ) , which interacts with RHOA that stimulates the serine / threonine Rho kinase ( ROK ) and thus the an kyrin phosphorylation - strengthened association with CD44 . On binding HA , CD44 associates with α 4 β 1 , which allows both molecules to use the partner’s signal transduction pathway , shown here as the activation of focal adhesion kinase ( FAK ) via SRC that is already bound by CD44 . In addition , the as sociation of α 4 β 1 with paxillin becomes tran siently weakened through protein kinase A ( PKA ) activation , which allows migration of the integrin – CD44 complex from the trailing edge to wards the leading lamella . c | Cleavage of CD44 accounts for the dynamic regulation between CD44 and HA during migration . Cleavage by a disintegrin and metalloproteinase domain 10 ( ADAM10 ) is triggered by Ca 2 + mobilization . Phospholipase C ( PLC ) catalyses hydrolysis of phospholipid phosphatidylinositol - 4 , 5 - bisphosphate ( PtdIns ( 4 , 5 ) P 2 ) to generate the signalling molecules and inositol - 1 , 4 , 5 - trisphosphate ( IP3 ; also known as Ins ( 1 , 4 , 5 ) P 3 ) and diaglycerol ( DAG ) , both of which are involved in Ca 2 + mobilization that catches calmodulin ( CAM ) . Pro - ADAM10 is released and activated to cleave the CD44 ectodomain . In addition , ADAM17 becomes activated through PKC and Rac . d | Mi grating tumour cells use CD44 for adhesion to and rolling on endothelial cells as the starting steps to wards extravasation . Rolling is initiated by weak binding of CD44 to CD62 on endothelial cells , but also on platelets and adherent leukocytes , which can provide a protective coat . Rolling is slowed down by the strong adhesion of CD44 to the HA coat of endothelial cells . HA binding initiates activa tion of CD44 so that it binds to the cytoskeletal linker proteins ankyrin and / or ezrin , radixin and moesin ( ERM ) , which link CD44 to filamen tous actin ( F - actin ) . CD44 moves from the trailing edge to the leading lamella so that the process of extravasation is initiated , and the activation - induced association with integrins has an essential role . e | The contribution of CD44 and CD44v6 to niche remodelling is based on CD44 – HA - initiated transcription of metalloproteinase 2 ( MMP2 ) , MMP9 , urokinase plasminogen activator receptor ( uPAR ) and cathepsin G . MMP2 and MMP9 bind to CD44 ; proMMP2 is cleaved by CD44v6 - associated MMP14 , which concomitantly allows for focal matrix degradation . Cathepsin G ( CTSG ) and MMP9 - activated transforming growth factor - β ( TGF β ) contribute to bone resorption and niche preparation for LICs and cancer - initiating cells ( CICs ; also known as cancer stem cells ) metastasizing in the bone . Cleavage of the extracellular domain of CD44 is frequently accompanied by the cleavage of the intracellular domain ( ICD ) by the presenilin – γ - secretase complex . The CD44 ICD acts together with CBP or p300 as a transcription factor , promoting , besides others , CD44 transcription . ECM , extracellular matrix . R E V I E W S 258 | APRIL 2011 | VOLUME 11 www . nature . com / reviews / cancer © 2011 Macmillan Publishers Limited . All rights reserved Notably , ectodomain cleavage of CD44 is highly preva - lent in tumours , and soluble CD44 levels in the serum correlate with tumour burden 92 . CD44 concentrates MMPs at the cell surface , where the production of uPAR , MMP2 and MMP9 is con - comitantly stimulated by the interaction between HA and CD44 ( REFS 93 , 94 ) , a process that was originally de scribed as occuring spontaneously in vivo in mam - mary carcinoma and malignant melanoma 95 , 96 . CD44 aggregation facilitates MMP binding 95 , and proMMP2 can become activated through CD44v - associated MMP14 , which is located in the leading lamellipodia . As cell - bound MMPs are protected from their inhibitors , this allows the focal degradation of the ECM to form space for invading cells 96 ( FIG . 2e ) . Cathepsin G , primarily secreted by osteoclasts , but also by tumour cells metas - tasizing to bone 97 , is another transcriptional target of HA – CD44 signalling 98 . Transforming growth factor - β ( TGFβ ) activation through CD44 - associated MMP9 , which promotes angiogenesis , invasion and metastasis 99 , also enhances osteoclast activity and bone resorption to create a niche 100 ( FIG . 2e ) . Ectodomain cleavage of CD44 triggers intramem - brane cleavage by the presenilin – γ - secretase com - plex 88 . The CD44 intracellular domain ( ICD ) acts as a transcription factor that potentiates the tran - scriptional co - activators CBP and p300 and leads to upregulated CD44 expression ( FIG . 2e ) . This pro - vides an addi tional mechanism through which CD44 binding regulates its own gene expression and that of other genes 25 . Furthermore , the CD44 ICD shows transforming activity , suggesting that CD44 shedding may not only affect metastasis , but also earlier events in tumorigenesis 101 . CD44 and the stem cell niche Current data indicate that CD44 also has an essential role in the crosstalk between stem cells and their niche , which supports stem cell maintenance . This function of CD44 has previously been characterized in HSCs and is not a new phenomenon . The composition of stem cell niches and niche func - tion . The fate of a cell in the developing organism is determined by its position 102 . ASCs reside in special - ized locations , niches , where their activity is minutely regulated 103 . Niches are composed of epithelial and mesenchymal cells and extracellular substrates that maintain and govern location , adhesion , retention , homing , mobilization , quiescence and activation , symmetric and asymmetric division , and differentia - tion 104 . However , the definition of mammalian stem cell niches is still provisional . It is frequently difficult to identify stem cells or niche cells with certainty in mammalian tissue , and which cells produce the fac - tors required for stem cell maintenance is poorly defined 105 . As a niche might function to prevent tum - origenesis , it is still under discussion whether CICs essentially require a niche . Moreover , as demon - strated for malignant melanoma , a niche might sup - port the reprogramming of metastatic tumour cells by exposing them to an embryonic microenvironment 106 . However , some findings suggest that CICs profit from a preformed niche , which supports survival and hom - ing 103 and can regulate the balance between quiescence and growth 107 . Indeed , as discussed above , selective depletion of LICs by CD44 - specific antibodies has provided evidence that ASCs and CICs might compete for the same niche 108 . On the basis of these findings and initial experimental data in different cell types , I suggest that three features of CD44 could be important for CIC niche interactions . The contribution of CD44 to matrix assembly . Stem cell niches are particularly rich in HA 109 . HA is also an essential component of the tumour matrix , and there is strong evidence that CD44 is involved in matrix assembly 110 , so the HA – CD44 association not only facilitates tumour cell arrest , but also modifies the tis - sue matrix to support colonization 98 , 111 . Perturbation in matrix components alters cell shape and intracel - lular tension , resulting in shifts in signalling events that affect gene expression 112 . This could be particu - larly important in the CIC niche where tumour cells that express HA can induce expression of HA in other cells that make up the niche 113 . Furthermore , CD44v6 is engaged in matrix assembly 114 . A stable CD44v4 – v7 , a CD44v6 and CD44v7 and a transient CD44v6 knock - down ( CD44v knockdown ) in a highly metastatic tumour line revealed a striking reduction in meta - static capacity , which was , at least in part , due to an altered tumour matrix 93 . The CD44v knockdown cells secrete a matrix that does not support ad hesion of CD44v wildtype or CD44v knockdown cells , whereas both cells readily adhere to the CD44v wildtype matrix . In fact , the CD44v knockdown is accompa - nied by a greatly reduced expression of HA synthase 3 ( HAS3 ) 93 , which is associated with a malignant phe - notype in many tumour types 115 ( FIG . 3a ) . Furthermore , a CD44v4 – 7 knockdown or CD44v6 knockdown and CD44v7 knockdown in a metastasizing tumour line resulted in a striking reduction in hepatoma - derived growth factor ( HDGF ) production 116 , which stimulates the growth of fibroblasts , endothelial cells and vascular smooth muscle cells and recruits mesenchymal stem cells 117 . Substantial differences were also observed in clusterin secretion that influences chemokine secretion and initiates stromal changes affecting intercellular communications 118 . The complement components C3a and C3b , absent in the CD44v knockdown , but abundant in the CD44v wildtype matrix 93 , might help to create an inflammatory milieu and recruit leukocytes 119 ( FIG . 3b ) . Capture activity of CD44 . By its nature as a trans - membrane proteoglycan , CD44 allows the local con centration of glycosaminoglycan - associating proteins , such as osteopontin ( OPN ) , FGF2 , VEGF and HGF , thereby increasing the capacity of these ligands to interact with their receptors and so lower - ing the threshold for signal transduction 120 . Binding of OPN , FGF2 , VEGF and HGF is of special interest for R E V I E W S NATURE REVIEWS | CANCER VOLUME 11 | APRIL 2011 | 259 © 2011 Macmillan Publishers Limited . All rights reserved (cid:48)(cid:67)(cid:86)(cid:87)(cid:84)(cid:71)(cid:2)(cid:52)(cid:71)(cid:88)(cid:75)(cid:71)(cid:89)(cid:85)(cid:2) (cid:94) (cid:2)(cid:37)(cid:67)(cid:80)(cid:69)(cid:71)(cid:84) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:24) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:21) (cid:87)(cid:50)(cid:35)(cid:52) (cid:42)(cid:41)(cid:40)(cid:2) (cid:42)(cid:38)(cid:41)(cid:40)(cid:2) (cid:87)(cid:50)(cid:35)(cid:2) (cid:37)(cid:38)(cid:19)(cid:21)(cid:2)(cid:37)(cid:38)(cid:20)(cid:24)(cid:2) (cid:53)(cid:71)(cid:84)(cid:75)(cid:80)(cid:71)(cid:2)(cid:82)(cid:84)(cid:81)(cid:86)(cid:71)(cid:67)(cid:85)(cid:71)(cid:85)(cid:2) (cid:37)(cid:21)(cid:67)(cid:2) (cid:37)(cid:21)(cid:68)(cid:2) (cid:46)(cid:48)(cid:23)(cid:2)(cid:10)(cid:72)(cid:84)(cid:67)(cid:73)(cid:79)(cid:71)(cid:80)(cid:86)(cid:85)(cid:11)(cid:2) (cid:46)(cid:91)(cid:79)(cid:82)(cid:74)(cid:2)(cid:80)(cid:81)(cid:70)(cid:71)(cid:2) (cid:49)(cid:50)(cid:48) (cid:40)(cid:41)(cid:40)(cid:20)(cid:2) (cid:42)(cid:41)(cid:40)(cid:2) (cid:67) (cid:69) (cid:68) (cid:70) (cid:41)(cid:39)(cid:47)(cid:2) (cid:48)(cid:87)(cid:69)(cid:78)(cid:71)(cid:87)(cid:85)(cid:2) (cid:42)(cid:35)(cid:53)(cid:2) (cid:47)(cid:39)(cid:54) (cid:42) (cid:35) (cid:53) (cid:21) (cid:2) (cid:42) (cid:35) (cid:53) (cid:21) (cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:53)(cid:115)(cid:53)(cid:2) (cid:47)(cid:47)(cid:50)(cid:85)(cid:2) (cid:56)(cid:39)(cid:41)(cid:40)(cid:2) the metastatic process 29 , 121 – 123 ( FIG . 3c ) . CD44v3 binds FGF2 and stimulates the proliferation of the underly - ing mesenchymal cells in the developing limb 124 and is required for uretric bud formation and mammary gland development 125 . OPN secretion is stimulated by HA 126 , and binds CD44v3 and CD44v6 ( REF . 127 ) . OPN is chemotactic and haptotactic for haematopoietic cells and is important for their arrest in the bone marrow niche 128 . In tumour cells , the OPN – CD44 interac - tion exerts a feedback on the tumour cell allowing it to migrate . Thus , Trp53 – / – ; Cd44 – / – mice have the same rate of primary tumour development as Trp53 – / – mice , but no metastatic progression 129 . Whether this might make CICs more mobile in their ‘niche’ has yet to be investigated . CD44 and modulation of the niche . CD44 may also be actively engaged in remodelling a pre - existing niche for CICs . Work by Kaplan et al . indicated that a niche for metastasizing CICs in advance of their arrival could be created by the activation of local fibroblasts through as yet unidentified tumour - derived factors 130 , 131 . A CD44v knockdown tumour line that has lost the ability to metastasize 114 might do so partly because of the absence of a pre - metastatic niche . The treatment of rats with conditioned medium from the parental , metastasizing line resulted in CD44v knockdown cells settling in lymph nodes and lung . A search for ‘niche - like’ structures and characteristic gene expression pro - files revealed marked upregulation of CXCL12 , CD31 and CD54 expression , pronounced CD49c , VEGFR1 , VEGFR2 , MMP9 , MMP13 and uPAR expression , and CD49d - positive and CD11b - positive cell clusters in the lymph nodes and lungs in advance of tumour cell arrival 93 , providing strong evidence that CD44v6 is engaged in creating a soluble matrix that is sufficient for premetastatic niche preparation with activation of resi - dent cells to recruit tumour , as well as haematopoietic , cells ( FIG . 3d ) . The CD44 crosstalk with the environment CD44 not only contributes to the assembly of the matrix surrounding the CICs , but importantly , the feedback from the microenvironment to stem cells and CICs also involves CD44 ( REF . 109 ) . There are excellent reviews on the multiple pathways through which CD44 is involved in signal transduction 3 , 132 . I focus exclusively on two aspects of particular interest with respect to CD44 as a CIC marker : the involvement of CD44 in EMT and apoptosis resistance . CD44 , with no catalytic activity , initiates signal transduction through associated trans - membrane kinases , cytosolic kinases and linker proteins , associating particularly in GEMs with the cytoplasmic tail of CD44 ( REFS 3 , 132 , 133 ) . Figure 3 | The contribution of CD44 to matrix assembly . CD44v6 is engaged in assem bling a matrix that strongly supports tumour cell adhesion and CD44v6 - dependent tumour cell mi gration ( parts a and b ) . This is a consequence of CD44v6 - stimulated hyaluronan ( HA ) synthase 3 ( HAS3 ) transcription and abundant secretion of high molecular mass HA , which catches hepatoma - derived growth factor ( HDGF ) , hepatocyte growth factor ( HGF ) , laminin 5 ( LN5 ) and LN5 fragments , several proteases and the comple ment components C3a and C3b . Recruitment and activation of host cells is further sup ported by the catcher activity of CD44v3 - associated gly cosaminoglycan ( GAG ) , which binds a large range of cytokines and chemokines , including HGF , fibroblast growth factor 2 ( FGF2 ) , osteopontin ( OPN ) and vascular en dothelial growth factor ( VEGF ) ( part c ) . CD44v6 - assembled matrix suffices ( in the absence of tumour cells ) for induction of a premetastatic niche in lymph nodes and the lung , characterized by endothelial cell and fibroblast activation and recruitment of myeloid progenitor cells ( part d ) . GEM , glycolipid - enriched microdomain . R E V I E W S 260 | APRIL 2011 | VOLUME 11 www . nature . com / reviews / cancer © 2011 Macmillan Publishers Limited . All rights reserved (cid:48)(cid:67)(cid:86)(cid:87)(cid:84)(cid:71)(cid:2)(cid:52)(cid:71)(cid:88)(cid:75)(cid:71)(cid:89)(cid:85)(cid:2) (cid:94) (cid:2)(cid:37)(cid:67)(cid:80)(cid:69)(cid:71)(cid:84) (cid:39)(cid:52)(cid:47)(cid:2) (cid:35)(cid:69)(cid:86)(cid:75)(cid:80)(cid:2) (cid:54)(cid:48)(cid:40) α (cid:50)(cid:45)(cid:37) (cid:54)(cid:41)(cid:40) β (cid:52)(cid:43)(cid:43) (cid:53)(cid:47)(cid:35)(cid:38) (cid:85)(cid:75)(cid:73)(cid:80)(cid:67)(cid:78)(cid:78)(cid:75)(cid:80)(cid:73) (cid:48)(cid:87)(cid:69)(cid:78)(cid:71)(cid:87)(cid:85) (cid:42) (cid:35) (cid:53) (cid:2) (cid:42)(cid:35)(cid:53)(cid:2) (cid:37)(cid:38)(cid:22)(cid:22)(cid:2) P CD44 and EMT . In advance of settling in metastatic organs , CICs have to leave the primary tumour mass , which is partly facilitated by EMT . EMT requires funda - mental changes in gene expression that disrupt epithelial polarity , are influenced by environmental factors 62 , 63 , 134 , 135 and can generate cells with stem cell properties 62 , 63 , 134 . In breast cancer cells , for example , tumour necrosis fac - tor ( TNF ) - mediated overexpression of SLUG and the constitutively active p65 subunit of nuclear factor - κB ( NF - κB ) result in a dramatic shift towards the CD44 + / CD24 + or CD44 + / CD24 – phenotype that is associated with stem cell behaviour 63 . Another central player is β - catenin , which , on activation , translocates to the nucleus and interacts with the TCF – LEF complex to turn on cell cycle - related genes , as well as gastrin , cyclooxygenase 2 ( COX2 ) , MMP7 , uPAR , CD44 , CD44v6 and MDR1 . Low levels of nuclear β - catenin may keep the balance between stemness and prolifera - tion , whereas higher levels initiate EMT , probably in cooperation with the CD44v6 – HGF – MET complex and co - stimulatory signals from the environment 136 . Besides this accessory function , CD44 and HA are important in regulating EMT 137 . Treatment with a scavenger of HA precursor molecules inhibits HA synthesis and reduces EMT and metastasis forma - tion 138 . In human breast cancer cells , EMT corresponds to the CD44 + / CD24 – CIC type 62 , in which the EMT phenotype is associated with strong CD44 upregula - tion and CD44 - linked changes in CXCL12 , platelet - derived growth factor ( PDGF ) , PKC , Akt , p38 MAPK , NF - κB and bone morphogenetic protein 7 ( BMP7 ) . Importantly , the invasiveness of breast cancer cells with an EMT phenotype can be inhibited by CD44 - specific antibodies 139 . In an elegant study Takahashi et al . 140 unravelled the link between HA , CD44 , TNFα and TGFβ in EMT . TNFα promotes CD44 expression and moesin phosphorylation through PKC that is accompanied by the formation of elongated actin stress fibres and CD44 – HA binding , cell – cell dissocia - tion and increased motility . The CD44 – moesin – actin complex , when located in clathrin - coated pits , asso - ciates with and stimulates TGFβRII and downstream SMAD2 and SMAD3 ( FIG . 4 ) . These findings provide clear evidence for TNFα initiating the signalling cas - cade through CD44 towards EMT . They do not exclude an additional contribution of CD44 by activating the TGFβ1 proform through associated MMPs 99 , 141 . CD44 and apoptosis resistance . Irradiation and drug resistance are major drawbacks in cancer therapy , and several lines of experimental evidence support the idea that apoptosis resistance is a feature of CICs rather than the mass of tumour cells 142 , 143 . In addition , there is ample evidence that the interaction of CD44 , predom - inantly of CD44v with HA , contributes to apoptosis resistance of CICs 66 , 109 , 142 – 145 . There are also examples in which CD44 crosslinking initiates apoptosis . However , apoptosis induction by CD44 – HA crosslinking is largely restricted to non - transformed cells with imma - ture leukocytes being most easily affected . Thus , together with the oncogenic transformation and the pronounced association of CD44 with oncogenes , CD44 – HA crosslinking initiates signals that promote cell survival in tumour cells . The crosstalk of CD44 with multidrug resistance genes accounts for an alter - native CD44 - mediated apoptosis resistance mechanism ( reviewed in REFS 137 , 146 ) . In many instances the CD44 - or CD44v - mediated activation of anti - apoptotic proteins is initiated through the association with receptor tyrosine kinases ( RTKs ) . CD44 co - immunoprecipitates with all ERBB RTK family members . The association of CD44 with ERBB2 and ERBB3 mediates heterodimeriza - tion and the activation of the receptor in response to neuregulin , which strongly promotes CIC apoptosis resistance 147 , 148 . The CD44 – HA interaction initiates ERBB2 phosphorylation , and the stimulation of HA production induces assembly of a lipid raft - integrated complex of ERBB2 , CD44 , ezrin , PI3K and the chap - erone molecules HSP90 and CDC37 . A blockade of the HA – CD44 interaction causes complex disassembly and inactivation of ERBB2 ( REF . 149 ) . In colon cancer , the HA – CD44 interaction and recruitment of ERBB2 also induces the transcription of COX2 initiated down - stream of CD44 through PI3K – Akt and β - catenin 150 . COX2 further strengthens apoptosis resistance and vascular permeability through prostaglandin E 2 expression ( FIG . 5a ) . MET is another important CD44 partner in apop - tosis resistance . CD44 promotes MET phos phorylation via CD44v3 - bound HGF , which is important in Figure 4 | The involvement of CD44 in epithelial – mesenchymal transition . Cancer - initi ating cells ( CICs ; also known as cancer stem cells ) require the adoption of a migratory phenotype for settlement in distant tissue . The process , called epithelial – mesenchymal tran sition ( EMT ) , involves CD44 and tumour necrosis factor - α ( TNF α ) - induced transcription . TNF α activates protein kinase C ( PKC ) that promotes hyaluronan synthase ( HAS ) transcription , as well as ezrin , radixin and moesin ( ERM ) phosphorylation . The CD44 – phosphorylated ERM complex initiates activation of transforming growth factor - β receptor 2 ( TGF β RII ) and the downstream SMAD signalling complex , which essentially con tribute to EMT . R E V I E W S NATURE REVIEWS | CANCER VOLUME 11 | APRIL 2011 | 261 © 2011 Macmillan Publishers Limited . All rights reserved (cid:48)(cid:67)(cid:86)(cid:87)(cid:84)(cid:71)(cid:2)(cid:52)(cid:71)(cid:88)(cid:75)(cid:71)(cid:89)(cid:85)(cid:2) (cid:94) (cid:2)(cid:37)(cid:67)(cid:80)(cid:69)(cid:71)(cid:84) (cid:39)(cid:52)(cid:47)(cid:2) (cid:35)(cid:77)(cid:86) (cid:35)(cid:77)(cid:86) (cid:48)(cid:52)(cid:41)(cid:19) (cid:50)(cid:43)(cid:21)(cid:45) (cid:50)(cid:43)(cid:21)(cid:45) (cid:50)(cid:43)(cid:21)(cid:45) (cid:67) (cid:68) (cid:69) (cid:47)(cid:47)(cid:50)(cid:25) (cid:50)(cid:46)(cid:37) γ (cid:53)(cid:52)(cid:37) (cid:53)(cid:52)(cid:37) (cid:53)(cid:52)(cid:37) P P P P P P (cid:42)(cid:53)(cid:50)(cid:25)(cid:18) (cid:37)(cid:38)(cid:37)(cid:21)(cid:25) (cid:39) (cid:52) (cid:36)(cid:36) (cid:20) (cid:39) (cid:52) (cid:36)(cid:36) (cid:21) (cid:48)(cid:52)(cid:41)(cid:19) (cid:39) (cid:52) (cid:36)(cid:36) (cid:20) (cid:39) (cid:52) (cid:36)(cid:36) (cid:21) (cid:39) (cid:52) (cid:36)(cid:36) (cid:22) (cid:39) (cid:52) (cid:36)(cid:36) (cid:22) (cid:37) (cid:49) (cid:58) (cid:20) (cid:50)(cid:41)(cid:39) (cid:20) (cid:37)(cid:49)(cid:58)(cid:20) (cid:48)(cid:87)(cid:69)(cid:78)(cid:71)(cid:87)(cid:85) (cid:50)(cid:45)(cid:37) (cid:53)(cid:49)(cid:53) (cid:41) (cid:35) (cid:36) (cid:19) (cid:41)(cid:52)(cid:36)(cid:20) (cid:47)(cid:71)(cid:86) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:24) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:21) (cid:82)(cid:84)(cid:81)(cid:42)(cid:36)(cid:39)(cid:41)(cid:40) (cid:42)(cid:36)(cid:39)(cid:41)(cid:40) (cid:52)(cid:67)(cid:85) (cid:39)(cid:52)(cid:45) (cid:39)(cid:92)(cid:84)(cid:75)(cid:80) (cid:42)(cid:41)(cid:40) (cid:36)(cid:35)(cid:38) (cid:36)(cid:37)(cid:46)(cid:15)(cid:20) (cid:36)(cid:37)(cid:46)(cid:15)(cid:20) (cid:36)(cid:37)(cid:46)(cid:15)(cid:58) (cid:46) (cid:36)(cid:37)(cid:46)(cid:15)(cid:58) (cid:46) (cid:36)(cid:35)(cid:38) colorectal cancer tumorigenesis 44 . CD44v6 also initiates MET activation through HGF binding . This requires the cytoplasmic tail of CD44 and the interaction with ERM proteins for activation of the Ras – MAPK path - way 151 . Haploinsufficiency of Met in Cd44 – / – mice revealed the interaction between CD44v6 , MET and ERM proteins to be vital , as these mice die at birth owing to defects in synaptogenesis and axon myeli - nation 152 . In addition , CD44v6 bind ing to the ECM also activates the PI3K – Akt pathway 127 , 153 and regu - lates Met transcription 115 ( FIG . 5b ) . Similar observations account for insulin - like growth factor 1 receptor and PDGFR activation through HA - stimulated CD44 in transformed cells 154 . The interaction between CD44 and RTK can also pro - ceed through proteases . For example , CD44v3 binds the proform of the heparin - binding EGF - like growth factor ( HBEGF ) 29 , which is cleaved by MMP7 that is recruited by CD44 . Cleaved HBEGF binds and activates ERBB4 , which activates cell survival pathways 125 , 155 ( FIG . 5c ) . The CD44 – MMP9 – TGFβ axis provides another RTK - independent means of rescuing metastasizing tumour cells from apoptosis 137 , 156 . Finally , two points already mentioned need to be stressed . Owing to its GEM location , CD44 also associ - ates with non - RTKs 157 . As membrane - attached molecular switches , SRC has a central role by linking various extra - cellular signals to crucial intracellular signalling path - ways 158 . Thus , the GEM location of CD44 is of particular importance for the involvement of CD44 in cell motility and signal transduc tion and accounts for the CD44 – HA binding - initiated crosstalk between RTKs , non - RTKs and linker proteins 133 . Second , CD44 - mediated upregu - lation of anti - apoptotic genes has been linked in many instances to CD44v expression 86 , 149 , 159 , 160 . CD44 and drug resistance . Drug resistance of CICs creates a major obstacle in cancer therapy , and both CD44 and HA contribute to drug resistance 161 , 162 . Although various mechanisms might explain this resistance , the rapid drug elimination by drug transporters clearly sup - ports CIC survival 163 . HYAL , as well as low molecular mass HA oligosaccharides , improve drug efficacy 164 , 165 , and HA – CD44 crosslinking regulates drug transporter expression 162 , 166 . MDR1 is associated with CD44 in GEMs and can be linked via CD44 with the actin cytoskeleton so that expression of both CD44 and MDR1 are concom - itantly regulated 137 , 161 ( FIG . 6a ) . An additional pathway of CD44 - promoted resistance to reactive oxygen species ( ROS ) - induced and cytotoxic drug - induced stress has been described in glioblastoma , in which CD44 down - regulation blocks growth and sensitizes cells to drugs . CD44 acts upstream of the mammalian tumour suppres - sive Hippo signalling pathway and promotes resistance to ROS - induced stress by attenuating the Hippo , JUN N - terminal kinase ( JNK ) and p53 pathways 167 ( FIG . 6b ) . Taken together , CD44 promotes EMT , motility , endothelial cell and niche adhesion , and actively con - tributes to niche generation and modulation . The tumour microenvironment also stimulates CD44 and CD44v6 , resulting in cell survival through the activa - tion or upregulation of anti - apoptotic proteins and drug resistance genes . EMT , tumour cell migration and resistance to apoptosis are associated with the metastatic phenotype and are characteristic features of CICs 168 – 170 . Thus , the functional activities of CD44 would seem to be essential for CICs . CD44 and the therapeutic attack of CICs Strategies to eliminate CICs aim to block CIC functions , to reverse CIC apoptosis resistance or to induce CIC differentiation 171 ( TABLE 1 ) . Owing to the involvement of Figure 5 | The CD44 – RTK cooperation and CIC apoptosis resistance . a | CD44 – hyaluronan ( HA ) binding , ac companied by activation of CD44 - associated SRC , ezrin phosphorylation and PI3K activation leads to the assembly of a complex that includes heat shock protein 70 ( HSP70 ) and the co - chaperone CDC37 , which promotes phosphorylation and activation of the ERBB2 – ERBB3 receptor tyrosine kinases ( RTKs ) . Particularly in colorectal cancer the CD44 – ERBB2 – ERBB3 complex provides a strong stimulus for cyclooxygenase 2 ( COX2 ) transcription . b | CD44v6 binds hepatocyte growth factor ( HGF ) and presents it to MET , where activation of MET and the downstream sig nal ling cascades require concomitant activation of CD44 - associated phosphorylated ezrin , radixin and moesin ( ERM ) and SRC . Signal ling via the Ras – MAPK and the PI3K – Akt pathway , which requires the signalling pathway assembled by the CD44 cytoplasmic tail , can be ini tiated without any additional stimuli by a CD44v6 - assembled matrix . c | CD44v3 binds pro - form of heparin binding EGF - like growth factor ( HBEGF ) , which becomes cleaved via CD44 - associated matrix metalloproteinase 7 ( MMP7 ) . HBEGF binds and activates ERBB4 . All of these CD44 – RTK associations strongly promote the activation of signalling cascades that block apoptosis and upregulate anti - apoptotic proteins . NRG1 , neuregulin ; PGE 2 , prostaglandin E 2 ; PLC γ , phospholipase C - γ . R E V I E W S 262 | APRIL 2011 | VOLUME 11 www . nature . com / reviews / cancer © 2011 Macmillan Publishers Limited . All rights reserved antibodies could interfere with signalling through CD44 and , depending on the second specificity , addi - tional signalling cascades important for CIC survival . Potential targets include EpCAM or CD133 , which are located in the same mem brane microdomains as CD44 ( REF . 146 ) . Importantly , many of the stratagies outlined in TABLE 1 have been carried out in syngeneic animal models . This helps clinical translation as side effects will not be hidden . Most importantly , central contribu - tions of CD44 to the crosstalk between CICs and the niche will not be missed . Summary CD44 has been defined as a CIC marker in many tumour entities , but it remains to be explored whether CICs preferentially express CD44s or CD44v . Clearly CD44 ( and potentially CD44v ) has biological functions that would be of value to CICs . This is mainly due to the bidirectional signalling between CD44 and its sur - roundings . The crosstalk of CD44 with transmembrane and cytoplasmic molecules functions as a potent ampli - fier of a variety of signals . The results from initial pre - clinical trials enforce the multiple benefits that CICs receive from CD44 and strengthen the point that CIC (cid:48)(cid:67)(cid:86)(cid:87)(cid:84)(cid:71)(cid:2)(cid:52)(cid:71)(cid:88)(cid:75)(cid:71)(cid:89)(cid:85)(cid:2) (cid:94) (cid:2)(cid:37)(cid:67)(cid:80)(cid:69)(cid:71)(cid:84) (cid:39)(cid:52)(cid:47)(cid:2) (cid:35)(cid:80)(cid:77)(cid:91)(cid:84)(cid:75)(cid:80)(cid:2) (cid:35)(cid:69)(cid:86)(cid:75)(cid:80)(cid:2) (cid:35)(cid:80)(cid:80)(cid:71)(cid:90)(cid:75)(cid:80)(cid:2)(cid:43)(cid:43) (cid:42) (cid:35) (cid:53) (cid:2) (cid:42) (cid:59) (cid:35) (cid:46) (cid:20) (cid:42) (cid:59) (cid:35) (cid:46) (cid:20) (cid:53)(cid:19)(cid:18)(cid:18)(cid:35) (cid:35)(cid:80)(cid:80)(cid:71)(cid:90)(cid:75)(cid:80)(cid:2)(cid:43)(cid:43) (cid:53)(cid:19)(cid:18)(cid:18)(cid:35) (cid:47)(cid:38)(cid:52)(cid:19) (cid:67) (cid:68) P P P P (cid:49)(cid:90)(cid:75)(cid:70)(cid:67)(cid:86)(cid:75)(cid:88)(cid:71)(cid:2)(cid:85)(cid:86)(cid:84)(cid:71)(cid:85)(cid:85)(cid:2)(cid:67)(cid:80)(cid:70)(cid:69)(cid:91)(cid:86)(cid:81)(cid:86)(cid:81)(cid:90)(cid:75)(cid:69)(cid:2)(cid:70)(cid:84)(cid:87)(cid:73) (cid:49)(cid:90)(cid:75)(cid:70)(cid:67)(cid:86)(cid:75)(cid:88)(cid:71)(cid:2)(cid:85)(cid:86)(cid:84)(cid:71)(cid:85)(cid:85)(cid:2)(cid:67)(cid:80)(cid:70)(cid:69)(cid:91)(cid:86)(cid:81)(cid:86)(cid:81)(cid:90)(cid:75)(cid:69)(cid:2)(cid:70)(cid:84)(cid:87)(cid:73) (cid:37)(cid:38)(cid:22)(cid:22)(cid:88)(cid:21) (cid:33) (cid:47)(cid:71)(cid:84)(cid:78)(cid:75)(cid:80) (cid:35)(cid:82)(cid:81)(cid:82)(cid:86)(cid:81)(cid:85)(cid:75)(cid:85) (cid:35)(cid:82)(cid:81)(cid:82)(cid:86)(cid:81)(cid:85)(cid:75)(cid:85)(cid:2)(cid:84)(cid:71)(cid:85)(cid:75)(cid:85)(cid:86)(cid:67)(cid:80)(cid:69)(cid:71) (cid:47)(cid:53)(cid:54)(cid:19)(cid:2)(cid:67)(cid:80)(cid:70)(cid:47)(cid:53)(cid:54)(cid:20) (cid:46)(cid:35)(cid:54)(cid:53)(cid:19)(cid:2)(cid:67)(cid:80)(cid:70)(cid:46)(cid:35)(cid:54)(cid:53)(cid:20) (cid:59)(cid:35)(cid:50) (cid:43)(cid:35)(cid:50)(cid:19)(cid:2)(cid:67)(cid:80)(cid:70)(cid:43)(cid:35)(cid:50)(cid:20) (cid:82)(cid:23)(cid:21) (cid:37)(cid:67)(cid:85)(cid:82)(cid:67)(cid:85)(cid:71)(cid:2)(cid:21)(cid:69)(cid:78)(cid:71)(cid:67)(cid:88)(cid:67)(cid:73)(cid:71) (cid:114)(cid:2)(cid:82)(cid:20)(cid:19)(cid:2)(cid:114)(cid:2)(cid:50)(cid:55)(cid:47)(cid:35) CD44 in the crosstalk with the tumour sur roundings , its coordinating activity in signal transduction through oncogene receptors and its stabilization of MDR genes , a blockade of CD44 should exert multi - factorial thera - peutic effects ( Supplementary information S3 ( figure ) ) . CD44 - based therapeutic strategies support this idea , but also indicate the risk of targeting a marker shared by CICs and ASCs that is widely expressed 172 . However , if CD44 is overexpressed in CICs , as a result of p53 mutation 173 , for example , this might represent a therapeutic window that allows the attack of CICs without affecting ASCs . Thus , distinct expression profiles of tumour sup pressor genes , oncogenes and CD44 partner molecules in CICs versus ASCs may contribute to selec tively targeting CICs . For exam - ple , a blockade of specific CD44v molecules ( CD44v7 in AML , CD44v6 – v10 in lymphoma and CD44v6 in AML , acute lymphocytic leukaemia , chronic lym - phocytic leukaemia and multiple myeloma 174 , 175 ) may be preferable to avoid interference with HSC engraft - ment . To more safely avoid side effects , I consider bis - pecific antibodies , which target two different antigens on a tumour cell , as demonstrated for CD44 and a leu - kaemia idiotype 176 , as most promising . Such bispecific Figure 6 | CICs , CD44 and drug resistance . a | Multidrug - resistant ( MDR ) proteins are associated with activated CD44 ( high molecular mass hyaluronan ( HA ) ligated and associated with phosphorylated ezrin , radixin and moesin ( ERM ) ) . Conversely , low molecular mass HA promotes CD44 and concomi tantly MDR protein internalization , which is accompanied by a substantial increase in cytotoxic drug sensitiv ity . Maintenance of the complex between CD44 , phosphorylated ERM , actin and MDR1 , as well as the recovery of the S100A – annexin II complex indicates internalization within caveolae and / or glycolipid - enriched microdomains ( GEMs ) so that en dosomal proteins may become degraded after ubiquitylation . As cancer - initi ating cells ( CICs ; also known as cancer stem cells ) , will mostly assemble a high molecular mass HA matrix , the CD44 - mediated stabiliza tion of MDR proteins within the cell membrane will contribute to drug resistance . b | An alternative mechanism of CD44v3 - sup ported drug resistance relies on the attenuation of the Hippo pathway , which is stimulated by membrane protein - attached merlin and leads to the upregulation of p53 , downregulation of in hibitor of apoptosis ( IAP ) proteins and pronounced cleavage of caspase 3 . CD44 has an essential role in attenuating these stress and apoptotic signalling pathways , and in CD44v3 - expressing tumour cells , merlin is replaced by phosphorylated ERM , so that IAP expression is increased and caspase 3 cleavage does not take place . HYAL2 , hyaluronidase 2 ; LATS , large tumour suppressor ; MST , mammalian sterile 20 - like kinase . R E V I E W S NATURE REVIEWS | CANCER VOLUME 11 | APRIL 2011 | 263 © 2011 Macmillan Publishers Limited . All rights reserved Table 1 | Examples of how to target CICs through CD44 Drug Study design Effect Suggested mechanisms Antibody CD44 - specific Mouse CML model Decreased engraftment , impaired ‘CML’ induction CD44 requirement for CML homing 74 CD44 - specific Human AML in mouse model * Reduced leukaemia repopulation Niche interaction required to maintain stem cell properties 73 CD44 - specific Human CD90 + HCC in mouse model * Local and metastatic growth suppres sion Impaired survival of CD90 + CD44 + HCC CICs 177 CD44v6 - specific Rat metastasizing pancreatic adenocarcinoma Retardation of metastasis formation Impaired embedding in metastatic organs 178 CD44v6 – mersantine - specific Patients with SSC and breast cancer Some stabilization of heavily pretreated patients Interrupted owing to lethal epidermal necroly sis 179 , 180 Bispecific CD44v6 – CD11b F ( ab’ ) 2 Rat metastasizing pancreatic adenocarcinoma Tumour growth retardation Antibody - dependent cellular cytotoxicity 181 Bispecific CD44 – idiotype Mouse B cell lymphoma Tumour growth retardation , reduced dis semination and prolonged survival Reduced homing and impaired lymphoma cell sur vival 176 Competitive protein or peptide Locally released soluble CD44 Soluble CD44 - transfected mouse breast cancer i . v . or s . c . Reduced tumorigenicity and invasion Apoptosis induction by interruption of CD44 – HA crosstalk 145 , disruption of HA - induced CD44 – MMP9 clustering and impaired collagen IV degra dation 96 Peptide competing for CD44v6 binding Human pancreatic adenocarcinoma in mouse model * Reduced angiogenesis , retarded tumour growth and metastasis formation Downmodulation of MET and VEGFR2 activa tion 31 Laminin α 5 chain peptide competing for CD44v3 binding Mouse melanoma i . v . or s . c . ( Matrigel ) Impaired tumour cell migration , inva sion and angiogenesis Prevents bioactivity of FGF2 ( REFS 182 , 183 ) Soluble CD44v3 – v10 – Fc fusion protein Human glioblastoma in mouse model * , i . cr . Growth inhibition and prolonged survival Traps HGF and other CD44 ligands , and sensitizes for apoptosis ( Hippo signalling ) 167 HA - CD44 crosstalk Low molecular mass HA Human CD133 + ovarian CICs in mouse model * , i . p . ( Matrigel ) . Reduced tumorigenicity and invasion Internalization of the CD44 - transporter complex and drug sensitization 184 , blockade of the genera tion of a HA / versican matrix 185 Low molecular mass HA Human MPNST in mouse model * , s . c . Growth inhibition Internalization of the CD44 - transporter complex and drug sensitization 165 HAS1 - antisense Human bladder cancer in mouse model * , s . c . Retarded growth and reduced angiogenesis Downregulation of CD44 , block in cell cycle ( ERBB2 pathway ) , increased apoptosis suscepti bility ( FAS – FAS ligand activation 186 ) Drug resistance HA – paclitaxel Human ovarian cancer in mouse model * , i . p . Inhibited tumour growth and invasion Drug targeting towards CD44 + ovarian CIC 187 HA – paclitaxel – – lipid ‘nanopar ticles’ Solid tumours , s . c . Tumour growth arrest Drug targeting towards CD44 + CIC 188 CD44 siRNA Chemoresistant breast cancer Increased drug sensitivity Elimination of drug - resistant CICs and thus Y - box binding protein 1 ( REF . 189 ) Inhibition of transcription Salinomycin Human and mouse breast cancer in mouse model * , s . c . and i . v . Growth inhibition and reduced metastasis Differentiation and loss of CSC gene expression ( CD44 ) 190 Gemini vitamin D analogue Human CD44 + breast cancer Reduced tumour growth Repression of CD44 expression in breast CICs 191 TGF b receptor inhibitor Glioblastoma Decrease in CD44 high glioblastoma CICs Inhibition of inhibitors of DNA - binding pro teins , known to have an important role in the control of stem cell self - renewal 192 AML , acute myeloid leukaemia ; CIC , cancer - initi ating cell ( also known as cancer stem cell ) ; CML , chronic myeloid leukaemia ; FGF2 , fibroblast growth factor 2 ; HCC , hepatocellular cancer ; HGF , hepatocyte growth factor ; i . cr . , intracranial ; i . p . , intraperitoneal ; i . v . , intravenous ; MMP , matrix metalloproteinase ; MPNST , malignant peripheral nerve sheath tumour ; s . c . , subcutaneous ; siRNA , small interfering RNA ; SSC , squamous cell carcinoma ; TGF b , transforming growth factor - b ; VEGFR2 , vascular endothelial growth factor receptor 2 . * Various strains of immunocompromised mice . R E V I E W S 264 | APRIL 2011 | VOLUME 11 www . nature . com / reviews / cancer © 2011 Macmillan Publishers Limited . All rights reserved 1 . Gallatin , W . M . , Weissman , I . L . & Butcher , E . C . A cell - surface molecule involved in organ - spe cific homing of lymphocytes . Nature 304 , 30 – 34 ( 1983 ) . 2 . Günthert , U . et al . A new variant of glycoprotein CD44 confers metastatic potential to rat carci noma cells . Cell 65 , 13 – 24 ( 1991 ) . First report on CD44 splice variants and their impor tance for metastatic potential . 3 . Naor , D . , Wallach - Dayan , S . B . , Zahalka , M . A . & Sionov , R . V . Involvement of CD44 , a mole cule with a thousand faces , in cancer dissemination . Semin . Cancer Biol . 18 , 260 – 267 ( 2008 ) . 4 . Ratajczak , M . Z . Cancer stem cells - - normal stem cells “Jedi” that went over to the “dark side” . Folia Histochem . Cytobiol . , 43 , 175 – 181 ( 2005 ) . 5 . Fábián , A . , Barok , M . , Vereb , G . & Szöllosi , J . Die hard : are cancer stem cells the Bruce Wil lises of tumor biology ? Cytometry A 75 , 67 – 74 ( 2009 ) . 6 . Allan . A . L . , Vantyghem , S . A . , Tuck , A . B . & Chambers , A . F . Tumor dormancy and cancer stem cells : implications for the biology and treatment of breast cancer metastasis . Breast Dis . 26 , 87 – 98 ( 2006 – 2007 ) . 7 . Sales , K . M . , Winslet , M . C . & Seifalian , A . M . Stem cells and cancer : an overview . Stem Cell Rev . 3 , 249 – 255 ( 2007 ) . 8 . Conway , A . E . et al . A Pluripotency and Self - Renewal Program Controls the Expansion of Geneti cally Unstable Cancer Stem Cells in Pluripotent Stem Cell - Derived Tumors . Stem Cells Oct 2 . [ Epub ahead of print ] ( 2008 ) . 9 . Adams , J . M . & Strasser , A . Is tumor growth sustained by rare cancer stem cells or dominant clones ? Cancer Res . 68 , 4018 – 4021 ( 2008 ) . 10 . Wang , J . C . Good cells gone bad : the cellular origins of cancer . Trends Mol . Med . 16 , 145 – 151 ( 2010 ) . 11 . Kuçi , S . et al . Adult stem cells as an alternative source of multipotential ( pluripotential ) cells in regenerative medicine . Curr . Stem Cell Res . Ther . 4 , 107 – 117 ( 2009 ) . 12 . Stamenkovic , I . , Amiot , M . , Pesando , J . M . & Seed , B . A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family . Cell 56 , 1057 – 1062 ( 1989 ) . 13 . Goldstein , L . A . et al . A human lymphocyte homing receptor , the hermes antigen , is related to cartilage proteoglycan core and link proteins . Cell 56 , 1063 – 1072 ( 1989 ) . References 12 and 13 describe clon ing of CD44 and characterization of CD44 as a member of the link protein family 14 . Aruffo , A . , Stamenkovic , I . , Melnick , M . , Underhill , C . B . & Seed , B . CD44 is the principal cell surface receptor for hyaluronate . Cell 61 , 1303 – 1313 ( 1990 ) . First description of HA as the major receptor for the leukocyte - homing molecule CD44 . 15 . Screaton , G . R . , Bell , M . V . , Jackson , D . G . , Cornelis , F . B . , Gerth , U . & Bell , J . I . Genomic struc ture of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alterna tively spliced exons . Proc . Natl Acad . Sci . USA 89 , 12160 – 12164 ( 1992 ) . First description of the complete intron – exon organization of the human CD44 gene . 16 . Idzerda , R . L . , Carter , W . G . , Nottenburg , C . , Wayner , E . A . , Gallatin , W . M . & St . John , T . Isola tion and DNA sequence of a cDNA clone encoding a lymphocyte adhesion receptor for high endothelium . Proc . Natl Acad . Sci . USA 86 , 4659 – 4663 ( 1989 ) . 17 . Goldstein , L . A . & Butcher , E . C . Identification of mRNA that encodes an alternative form of H - CAM ( CD44 ) in lymphoid and nonlymphoid tissues . Immunogenetics 32 , 389 – 397 ( 1990 ) . 18 . Peach , R . J . , Hollenbaugh , D . , Stamenkovic , I . & Aruffo , A . Identification of hyaluronic acid binding sites in the extracellular domain of CD44 . J . Cell Biol . 122 , 257 – 264 ( 1993 ) . 19 . Ishii , S . , Ford , R . , Thomas , P . , Nachman , A . , Steele , G . Jr . & Jessup , J . M . CD44 participates in the adhesion of human colorectal carcinoma cells to laminin and type IV collagen . Surg . Oncol . 2 , 255 – 264 ( 1993 ) . 20 . Jalkanen , S . & Jalkanen , M . Lymphocyte CD44 binds the COOH - terminal heparin - binding do main of fibronectin . J . Cell Biol . 116 , 817 – 825 ( 1992 ) . 21 . Konstantopoulos , K . & Thomas , S . N . Cancer cells in transit : the vascular interactions of tumor cells . Annu . Rev . Biomed . Eng . 11 , 177 – 202 ( 2009 ) . 22 . Toyama - Sorimachi , N . & Miyasaka , M . A novel ligand for CD44 is sulfated proteoglycan . Int . Immunol . 6 , 655 – 660 ( 1994 ) . 23 . Greenfield , B . et al . Characterization of the heparan sulfate and chondroitin sulfate assembly sites in CD44 . J . Biol . Chem . 274 , 2511 – 2517 ( 1999 ) . 24 . Screaton , G . R . , Bell , M . V . , Bell , J . I . & Jackson , D . G . The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp - 1 ( CD44 ) homing receptor . Comparison of all 10 variable exons between mouse , human , and rat . J . Biol . Chem . 268 , 12235 – 12238 ( 1993 ) . 25 . Okamoto , I . et al . Proteolytic release of CD44 intracellular domain and its role in the CD44 sig naling pathway . J . Cell Biol . 155 , 755 – 762 ( 2001 ) . 26 . Kalnina , Z . , Zayakin , P . , Silina , K . & Liné , A . Alterations of pre - mRNA splicing in cancer . Genes Chromosomes Cancer 42 , 342 – 357 ( 2005 ) . 27 . Neame , S . J . & Isacke , C . M . The cytoplasmic tail of CD44 is required for basolateral localiza tion in ephitelial MDCK cells but does not mediate association with the detergent - insoluble cy toskeleton of fibroblasts . J . Cell Biol . 121 , 1299 – 1310 ( 1993 ) . 28 . Ruiz . P . , Schwärzler , C . & Günthert , U . CD44 isoforms during differentiation and development . Bioessays 17 , 17 – 24 ( 1995 ) . 29 . Bennett , K . L . et al . CD44 isoforms containing exon v3 are responsible for the presentation of heparin - binding growth factor . J . Cell Biol . 128 , 687 – 698 ( 1995 ) . 30 . Orian - Rousseau , V . & Ponta , H . Adhesion proteins meet receptors : a common theme ? Adv . Can cer Res . 101 , 63 – 92 ( 2008 ) . 31 . Tremmel , M . et al . A CD44v6 peptide reveals a role of CD44 in VEGFR - 2 signaling and angio genesis . Blood 114 , 5236 – 5244 ( 2009 ) . 32 . Lesley , J . , Hyman , R . & Kincade , P . W . CD44 and its interaction with extracellular matrix . Adv . Immunol . 54 , 271 – 335 ( 1993 ) . 33 . Liu , D . & Sy , M . S . Phorbol myristate acetate stimulates the dimerization of CD44 involving a cysteine in the transmembrane domain . J . Immunol . 159 , 2702 – 2711 ( 1997 ) . 34 . Oliferenko , S . et al . Analysis of CD44 - containing lipid rafts : Recruitment of annexin II and stabili zation by the actin cytoskeleton . J . Cell Biol . 146 , 843 – 854 ( 1999 ) . 35 . Föger , N . , Marhaba , R . & Zöller , M . Raft associated interaction of CD44 with the cytoskeleton . J . Cell Science 114 , 1169 – 1178 ( 2001 ) . Describes for the first time the importance of the GEM localization of CD44 as a co - receptor in signal transduction and cytoskeleton organi zation . 36 . Lokeshwar , V . B . , Fregien , N . & Bourguignon , L . Y . Ankyrin - binding domain of CD44 ( Gp85 ) is required for the expression of hyaluronic acid - mediated adhesion function . J . Cell Biol . 126 , 1099 – 1109 ( 1994 ) . 37 . Fehon , R . G . , McClatchey , A . I . & Bretscher , A . Organizing the cell cortex : the role of ERM pro teins . Nature Rev . Mol . Cell Biol . 11 , 276 – 287 ( 2010 ) . 38 . Mori , T . , Kitano , K . , Terawaki , S . , Maesaki , R . , Fukami , Y . & Hakoshima , T . Structural basis for CD44 recognition by ERM proteins . J . Biol . Chem . 283 , 29602 – 29612 ( 2008 ) . 39 . Stamenkovic , I . & Yu , Q . Merlin , a “Magic” Linker between Extracellular Cues and Intracellular Signaling Pathways that Regulate Cell . M otility , Proliferation , and Survival . Curr . Protein Pept . Sci . 11 , 471 – 484 ( 2010 ) . 40 . Virchow , R . L . K . in Cellular Pathology ( ed . Hirschwald A ) , Berlin ( 1858 ) . 41 . Lapidot , T . et al . A cell initiating human acute myeloid leukaemia after transplantation into SCID mice . Nature 367 , 645 – 648 ( 1994 ) . Definition of leukemia - initiating cells by their growth in SCID mice . 42 . Lessard , J . & Sauvageau , G . Bmi - 1 determines the proliferative capacity of normal and leukae mic stem cells . Nature 423 , 255 – 260 ( 2003 ) . 43 . Elenbaas , B . et al . Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells . Genes Dev . 15 , 50 – 65 ( 2001 ) . 44 . Karnoub , A . E . et al . Mesenchymal stem cells within tumour stroma promote breast cancer metas tasis . Nature 449 , 557 – 563 ( 2007 ) . 45 . Ponti , D . et al . Isolation and in vitro propagation of tumorigenic breast cancer cells with stem / progenitor cell properties . Cancer Res . 65 , 5506 – 5511 ( 2005 ) . 46 . Zhou , S . et al . The ABC transporter Bcrp1 / ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side - population phenotype . Nature Med . 7 , 1028 – 1034 ( 2001 ) . 47 . Lobo , N . A . , Shimono , Y . , Qian , D . & Clarke , M . F . The Biology of Cancer Stem Cells . Annu . Rev . Cell . Dev . Biol . 23 , 675 – 688 ( 2007 ) . 48 . Tárnok , A . , Ulrich , H . & Bocsi , J . Phenotypes of stem cells from diverse origin . Cytometry A 77 , 6 – 10 ( 2010 ) . 49 . Takahashi , K . & Yamanaka , S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors . Cell 126 , 663 – 676 ( 2006 ) . 50 . Huangfu , D . et al . Induction of pluripotent stem cells from primary human fibroblasts with only Oct4 and Sox2 . Nature Biotechnol . 26 , 1269 – 1275 ( 2008 ) . 51 . Suzuki , H . I . , Yamagata , K . , Sugimoto , K . , Iwamoto , T . , Kato , S . & Miyazono , K . Modulation of microRNA processing by p53 . Nature 460 , 529 – 533 ( 2009 ) . 52 . Kashyap , V . et al . Regulation of stem cell pluripotency and differentiation involves a mutual regu latory circuit of the NANOG , OCT4 , and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs . Stem Cells Dev . 18 , 1093 – 1108 ( 2009 ) . 53 . Cerdan , C . & Bhatia , M . Novel roles for Notch , Wnt and Hedgehog in hematopoesis derived from human pluripotent stem cells . Int . J . Dev . Biol . 54 , 955 – 963 ( 2010 ) . 54 . Kwong , L . N . & Dove , W . F . APC and its modifiers in colon cancer . Adv . Exp . Med . Biol . 656 , 85 – 106 ( 2009 ) . 55 . Wielenga , V . J . et al . Expression of CD44 in Apc and Tcf mutant mice implies regulation by the WNT pathway . Am . J . Pathol . 154 , 515 – 523 ( 1999 ) . 56 . Bourguignon , L . Y . , Spevak , C . C . , Wong , G . , Xia , W . & Gilad , E . Hyaluronan - CD44 interac tion with protein kinase C ( epsilon ) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA - 21 , leading to down - regulation of the tumor suppressor protein PDCD4 , anti - apoptosis , and chemotherapy resistance in breast tumor cells . J . Biol . Chem . 284 , 26533 – 26546 ( 2009 ) . Provides evidence for the involvement of CD44 in produc tion of the oncogene miRNA - 21 . 57 . Hao , J . et al . Co - expression of CD147 ( EMMPRIN ) , CD44v3 – 10 , MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression . Br . J . Cancer 103 , 1008 – 1018 ( 2010 ) . 58 . Huang , Q . et al . The microRNAs miR - 373 and miR - 520c promote tumour invasion and metasta sis . Nature Cell Biol . 10 , 202 – 210 ( 2008 ) . 59 . Skotheim , R . I . & Nees , M . Alternative splicing in cancer : noise , functional , or systematic ? Int . J . Biochem . Cell Biol . 39 , 1432 – 1449 ( 2007 ) . 60 . Srebrow , A . & Kornblihtt , A . R . The connection between splicing and cancer . J . Cell Sci . 119 , 2635 – 2641 ( 2006 ) . 61 . Yang , J . & Weinberg , R . A . Epithelial - mesenchymal transition : at the crossroads of develop ment and tumor metastasis . Dev . Cell 14 , 818 – 829 ( 2008 ) . 62 . Blick , T . et al . Epithelial mesenchymal transition traits in human breast cancer cell lines parallel the CD44 ( hi / ) CD24 ( lo / - ) stem cell phenotype in human breast cancer . J . Mammary Gland Biol . Neoplasia 15 , 235 – 252 ( 2010 ) . 63 . Bhat - Nakshatri , P . et al . SLUG / SNAI2 and tumor necrosis factor generate breast cells with CD44 + / CD24 - phenotype . BMC Cancer 10 , 411 ( 2010 ) . function might be disrupted by the blockade of this one molecule . Though many uncharted areas on the CD44 map have to be explored before an optimal translation into a CD44 - based therapeutic CIC attack can be real - ized , it is my view that high efficacy can be achieved with a wide range of drugs as far as side effects can be prevented . In addition to building on overexpression , or the more restricted expression of CD44v isoforms , conjugated drugs , which target a second CIC marker , might provide a convincing solution . R E V I E W S NATURE REVIEWS | CANCER VOLUME 11 | APRIL 2011 | 265 © 2011 Macmillan Publishers Limited . All rights reserved 64 . Smart , N . & Riley , P . R . The stem cell movement . Circ . Res . 2008 May 23 ; 102 ( 10 ) , 1155 – 1168 . 65 . Almond , A . Hyaluronan . Cell . Mol . Life Sci . 64 , 1591 – 1596 ( 2007 ) . 66 . Toole , B . P . Hyaluronan : from extracellular glue to pericellular cue . Nature Rev . Cancer 4 , 528 – 539 ( 2004 ) . Excellent Review on the close functional connection between HA and its recep tor CD44 . 67 . Lapidot , T . , Dar , A . & Kollet , O . How do stem cells find their way home ? Blood 106 , 1901 – 1910 ( 2005 ) . 68 . Miyake , K . , Medina , K . L . , Hayashi , S . , Ono , S . , Hamaoka , T . & Kincade , P . W . Monoclonal anti bodies to Pgp - 1 / CD44 block lympho - hemopoiesis in long - term bone marrow cultures . J . Exp . Med . 171 , 477 – 488 ( 1990 ) . 69 . Lundell , B . I . , Mccarthy , J . B . , Kovach , N . L . & Verfaillie , C . M . Activation of beta1 integrins on CML progenitors reveals cooperation between beta1 integrins and CD44 in the regulation of adhesion and proliferation . Leukemia 11 , 822 – 829 ( 1997 ) . 70 . Ratajczak , M . Z . et al . Heterogeneous populations of bone marrow stem cells - - are we spotting on the same cells from the different angles ? Folia Histochem . Cytobiol . 42 , 139 – 146 ( 2004 ) . 71 . Avigdor , A . et al . CD44 and hyaluronic acid cooperate with SDF - 1 in the trafficking of human CD34 + stem / progenitor cells to bone marrow . Blood 103 , 2981 – 2989 ( 2004 ) . 72 . Liu , J . & Jiang , G . CD44 and hematologic malignancies . Cell . Mol . Immunol . 3 , 359 – 365 ( 2006 ) . 73 . Jin , L . , Hope , K . J . , Zhai , Q . , Smadja - Joffe , F . & Dick , J . E . Targeting of CD44 eradicates hu man acute myeloid leukemic stem cells . Nature Med . 12 , 1167 – 1174 ( 2006 ) . Provides convincing evidence that the CD44 – niche interaction is required for AML – CIC survival . 74 . Krause , D . S . , Lazarides , K . , von Andrian , U . H . & Van Etten , R . A . Requirement for CD44 in homing and engraftment of BCR - ABL - expressing leukemic stem cells . Nature Med . 12 , 1175 – 1180 ( 2006 ) . Defines CD44 as the homing receptor for CML ( see also reference 73 ) . 75 . Zöller , M . , Rajasagi , M . , Vitacolonna , M . & Luft , T . Thymus repopulation after allogeneic recon stitution in hematological malignancies . Exp . Hematol . , 35 , 1891 – 1905 ( 2007 ) . 76 . Colmone , A . , Amorim , M . , Pontier , A . L . , Wang , S . , Jablonski , E . & Sipkins , D . A . Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells . Science 322 , 1861 – 1865 ( 2008 ) . Convincing demonstration that CICs usurp and modu late stem cell niches so that the niche no longer fulfils the requirement of ASCs . 77 . Ropponen , K . et al . Tumor cell - associated hyaluronan as an unfavorable prognostic factor in colo rectal cancer . Cancer Res . 58 , 342 – 347 ( 1998 ) . 78 . Kim , H . R . et al . Hyaluronan facilitates invasion of colon carcinoma cells in vitro via interaction with CD44 . Cancer Res . 64 , 4569 – 4576 ( 2004 ) . 79 . Siegelman , M . H . , Stanescu , D . & Estess , P . The CD44 - initiated pathway of T - cell extravasa tion uses VLA - 4 but not LFA - 1 for firm adhesion . J . Clin . Invest . 105 , 683 – 691 ( 2000 ) . 80 . Lesley , J . , English , N . M . , Gál , I . , Mikecz , K . , Day , A . J . & Hyman , R . Hyaluronan binding prop erties of a CD44 chimera containing the link module of TSG - 6 . J . Biol . Chem . 277 , 26600 – 26608 ( 2002 ) . 81 . Lamontagne , C . A . & Grandbois , M . PKC - induced stiffening of hyaluronan / CD44 linkage ; lo cal force measurements on glioma cells . Exp . Cell Res . 314 , 227 – 236 ( 2008 ) . 82 . Thomas , L . , Byers , H . R . , Vink , J . & Stamenkovic , I . CD44H regulates tumor cell migration on hyaluronate - coated substrate . J . Cell Biol . 118 , 971 – 977 ( 1992 ) . 83 . Oliferenko , S . , Kaverina , I . , Small , J . V . & Huber , L . A . Hyaluronic acid ( HA ) binding to CD44 activates Rac1 and induces lamellipodia outgrowth . J . Cell Biol . 148 , 1159 – 1164 ( 2000 ) . 84 . Bustelo , X . R . Regulatory and signaling properties of the Vav family . Mol . Cell Biol . 20 , 1461 – 1477 ( 2000 ) . 85 . Bourguignon , L . Y . , Singleton , P . A . , Zhu , H . & Diedrich , F . Hyaluronan - mediated CD44 interac tion with RhoGEF and Rho kinase promotes Grb2 - associated binder - 1 phosphorylation and phosphatidylinositol 3 - kinase signaling leading to cytokine ( macrophage - colony stimulating factor ) production and breast tumor progression . J . Biol . Chem . 278 , 29420 – 29434 ( 2003 ) . 86 . Bourguignon , L . Y . Hyaluronan - mediated CD44 activation of RhoGTPase signaling and cy toskeleton function promotes tumor progression . Semin . Cancer Biol . 18 , 251 – 259 ( 2008 ) . 87 . Marhaba , R . , Freyschmidt - Paul , P . & Zöller , M . In vivo CD44 - CD49d complex formation in autoimmune disease has consequences on T cell activation and apoptosis resistance . Eur . J . Immunol . 36 , 3017 – 3032 ( 2006 ) . 88 . Nagano , O . & Saya , H . Mechanism and biological significance of CD44 cleavage . Cancer Sci . 95 , 930 – 935 ( 2004 ) . 89 . Nagano , O . et al . Cell - matrix interaction via CD44 is independently regulated by different metallo - proteinases activated in response to extracellular Ca ( 2 + ) influx and PKC activation . J . Cell Biol . 165 , 893 – 902 ( 2004 ) . 90 . Nakamura , H . et al . Constitutive and induced CD44 shedding by ADAM - like proteases and mem brane - type 1 matrix metalloproteinase . Cancer Res . 64 , 876 – 882 ( 2004 ) . 91 . Sugahara , K . N . et al . Chondroitin sulfate E fragments enhance CD44 cleavage and CD44 - dependent motility in tumor cells . Cancer Res . 68 , 7191 – 7199 ( 2008 ) . 92 . Okamoto , I . et al . Proteolytic cleavage of the CD44 adhesion molecule in multiple human tu mors . Am . J . Pathol . 160 , 441 – 447 ( 2002 ) . 93 . Jung , T . et al . CD44v6 dependence of premetastatic niche preparation by exosomes . Neoplasia 11 , 1093 – 1105 ( 2009 ) . 94 . Desai , B . , Ma , T . , Zhu , J . & Chellaiah , M . A . Characterization of the expression of variant and standard CD44 in prostate cancer cells : identification of the possible molecular mechanism of CD44 / MMP9 complex formation on the cell surface . J . Cell . Biochem . 108 , 272 – 284 ( 2009 ) . 95 . Bourguignon , L . Y . et al . CD44v ( 3 , 8 – 10 ) is involved in cytoskeleton - mediated tumor cell migra tion and matrix metalloproteinase ( MMP - 9 ) association in metastatic breast cancer cells . J . Cell . Physiol . 176 , 206 – 215 ( 1998 ) . 96 . Yu , Q . & Stamenkovic , I . Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44 - mediated tumor invasion . Genes Dev . 13 , 35 – 48 ( 1999 ) . 97 . Wilson , T . J . , Nannuru , K . C . , Futakuchi , M . , Sadanandam , A . & Singh , R . K . Cathepsin G . en hances mammary tumor - induced osteolysis by generating soluble receptor activator of nuclear factor - kappaB ligand . Cancer Res . 68 , 5803 – 5811 ( 2008 ) . 98 . Hill , A . , McFarlane , S . , Johnston , P . G . & Waugh , D . J . The emerging role of CD44 in regulat ing skeletal micrometastasis . Cancer Lett . 237 , 1 – 9 ( 2006 ) . 99 . Yu , Q . & Stamenkovic , I . Cell surface - localized matrix metalloproteinase - 9 proteolytically acti vates TGF - beta and promotes tumor invasion and angiogenesis . Genes Dev . 14 , 163 – 176 ( 2000 ) . 100 . Wilson , T . J . , Nannuru , K . C . & Singh , R . K . Cathepsin G - mediated activation of pro - matrix met alloproteinase 9 at the tumor - bone interface promotes transforming growth factor - beta sig naling and bone destruction . Mol . Cancer Res . 7 , 1224 – 1233 ( 2009 ) . 101 . Pelletier , L . et al . Gamma - secretase - dependent proteolysis of CD44 promotes neoplastic transfor - mation of rat fibroblastic cells . Cancer Res . 66 , 3681 – 3687 ( 2006 ) . 102 . Wolpert , L . One hundred years of positional information . Trends Genet . 12 , 359 – 364 ( 1996 ) . 103 . Li , L . & Neaves , W . B . Normal stem cells and cancer stem cells : the niche matters . Cancer Res . 66 , 4553 – 4557 ( 2006 ) . 104 . Diaz - Flores , L . Jr . , Madrid , J . F . , Gutierrez , R . , Varela , F . , Alvarez - Argüelles , H . & Diaz - Flo res , L . Adult stem and transit - amplifying cell location . Histol . Histopathol . 21 , 995 – 1027 ( 2006 ) . 105 . Arai , F . et al . Tie2 / angiopoietin - 1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche . Cell 118 , 149 – 161 ( 2004 ) . 106 . Hendrix , M . J . , Seftor , E . A . , Seftor , R . E . , Kasemeier - Kulesa , J . , Kulesa , P . M . & Postovit , L . M . Reprogramming metastatic tumour cells with embryonic microenvironments . Nature Rev . Cancer 7 , 246 – 255 ( 2007 ) . 107 . Morrison , S . J . & Spradling , A . C . Stem cells and niches : mechanisms that promote stem cell maintenance throughout life . Cell 132 , 598 – 611 ( 2008 ) . 108 . Williams , D . A . & Cancelas , J . A . Leukaemia : niche retreats for stem cells . Nature 444 , 827 – 828 ( 2006 ) . 109 . Stern , R . Association between cancer and “acid mucopolysaccharides” : an old concept comes of age , finally . Semin . Cancer Biol . 18 , 238 – 243 ( 2008 ) . 110 . Girish , K . S . & Kemparaju , K . The magic glue hyaluronan and its eraser hyaluronidase : a biologi cal overview . Life Sci . 80 , 1921 – 1943 ( 2007 ) . 111 . Kuhn , N . Z . & Tuan , R . S . Regulation of stemness and stem cell niche of mesenchymal stem cells : implications in tumorigenesis and metastasis . J . Cell . Physiol . 222 , 268 – 277 ( 2010 ) . 112 . Wang , N . , Tytell , J . D . & Ingber , D . E . Mechanotransduction at a distance : mechanically cou pling the extracellular matrix with the nucleus . Nature Rev . Mol . Cell Biol . 10 , 75 – 82 ( 2009 ) . 113 . Itano , N . & Kimata , K . Altered hyaluronan biosynthesis in cancer progression . Semin . Cancer Biol . 18 , 268 – 274 ( 2008 ) . 114 . Klingbeil , P . , Marhaba , R . , Jung , T . , Kirmse , R . , Ludwig , T . & Zöller , M . CD44 variant iso forms promote metastasis formation by a tumor cell - matrix cross - talk that supports adhesion and apoptosis resistance . Mol . Cancer Res . 7 , 168 – 179 ( 2009 ) . 115 . Adamia , S . , Maxwell , C . A . & Pilarski , L . M . Hyaluronan and hyaluronan synthases : potential therapeutic targets in cancer . Curr . Drug Targets . Cardiovasc . Haematol . Disord . 5 , 3 – 14 ( 2005 ) . 116 . Jung , T . Molekulare Grundlagen des Beitrags varianter CD44 - Isoformen zur Apoptoseresistenz und Präparation einer prämetastatischen Nische . PhD Thesis , 2010 , Karslruhe Institute of Tech nology , Karlsruhe , Germany . 117 . Zhang , J . , Ren , H . , Yuan , P . , Lang , W . , Zhang , L . & Mao , L . Down - regulation of hepatoma - de rived growth factor inhibits anchorage - independent growth and invasion of non - small cell lung cancer cells . Cancer Res . 66 , 18 – 23 ( 2006 ) . 118 . Pucci , S . , Mazzarelli , P . , Nucci , C . , Ricci , F . & Spagnoli , L . G . CLU “in and out” : looking for a link . Adv . Cancer Res . 105 , 93 – 113 ( 2009 ) . 119 . Peerschke , E . I . , Yin , W . & Ghebrehiwet , B . Complement activation on platelets : implications for vascular inflammation and thrombosis . Mol . Immunol . 47 , 2170 – 2175 ( 2010 ) . 120 . Couchman , J . R . Transmembrane Signaling Proteoglycans . Annu . Rev . Cell Dev . Biol . 26 , 89 – 114 ( 2010 ) . 121 . Wai , P . Y . & Kuo , P . C . Osteopontin : regulation in tumor metastasis . Cancer Metastasis Rev . 27 , 103 – 118 ( 2008 ) . 122 . Berdiaki , A . , Nikitovic , D . , Tsatsakis , A . , Katonis , P . , Karamanos , N . K . & Tzanakakis , G . N . bFGF induces changes in hyaluronan synthase and hyaluronidase isoform expression and modulates the migration capacity of fibrosarcoma cells . Biochim . Biophys . Acta 1790 , 1258 – 1265 ( 2009 ) . 123 . van der Voort , R . et al . Heparan sulfate - modified CD44 promotes hepatocyte growth fac tor / scatter factor - induced signal transduction through the receptor tyrosine kinase c - Met . J . Biol . Chem . 274 , 6499 – 6506 ( 1999 ) . 124 . Sherman , L . , Wainwright , D . , Ponta , H . & Herrlich , P . A splice variant of CD44 expressed in the apical ectodermal ridge presents fibroblast growth factors to limb mesenchyme and is re quired for limb outgrowth . Genes Dev . 12 , 1058 – 1071 ( 1998 ) . 125 . Yu , W . H . , Woessner , J . F . Jr . , McNeish , J . D . & Stamenkovic , I . CD44 anchors the assembly of matrilysin / MMP - 7 with heparin - binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling . Genes Dev . 16 , 307 – 323 ( 2002 ) . One of the first descriptions of the cooperativity between proteoglycan activities of CD44 , MMPs , growth factors and their receptors with tyrosine kinase activity . 126 . Kim , M . S . et al . Hyaluronic acid induces osteopontin via the phosphatidylinositol 3 - kinase / Akt pathway to enhance the motility of human glioma cells . Cancer Res . 65 , 686 – 691 ( 2005 ) . 127 . Weber , G . F . Molecular mechanisms of metastasis . Cancer Lett . 270 , 181 – 190 ( 2008 ) . 128 . Kollet , O . et al . Osteoclasts degrade endosteal components and promote mobilization of hemato - poietic progenitor cells . Nature Med . 12 , 657 – 664 ( 2006 ) . 129 . Weber , G . F . , Bronson , R . T . , Ilagan , J . , Cantor , H . , Schmits , R . & Mak , T . W . Absence of the CD44 gene prevents sarcoma metastasis . Cancer Res . 62 , 2281 – 2286 ( 2002 ) . 130 . Kaplan , R . N . et al . VEGFR1 - positive haematopoietic bone marrow progenitors initiate the pre - metastatic niche . Nature 438 , 820 – 827 ( 2005 ) . 131 . Barnhart , B . C . & Simon , M . C . Metastasis and stem cell pathways . Cancer Metastasis Rev . 26 , 261 – 271 ( 2007 ) . R E V I E W S 266 | APRIL 2011 | VOLUME 11 www . nature . com / reviews / cancer © 2011 Macmillan Publishers Limited . All rights reserved 132 . Ponta , H . , Sherman , L . & Herrlich , P . A . CD44 : from adhesion molecules to signalling regula tors . Nature Rev . Mol . Cell Biol . 4 , 33 – 45 ( 2003 ) . 133 . Marhaba , R . & Zöller , M . CD44 in cancer progression : adhesion , migration and growth regula tion . J . Mol . Histol . 35 , 211 – 231 ( 2004 ) . 134 . Mani , S . A . et al . The epithelial - mesenchymal transition generates cells with properties of stem cells . Cell 133 , 704 – 715 ( 2008 ) . 135 . Ahmed , N . , Abubaker , K . , Findlay , J . & Quinn , M . Epithelial mesenchymal transition and can cer stem cell - like phenotypes facilitate chemoresistance in recurrent ovarian cancer . Curr . Can cer Drug Targets . 10 , 268 – 278 ( 2010 ) . 136 . Wong , N . A . & Pignatelli , M . Beta - catenin - - a linchpin in colorectal carcinogenesis ? Am . J . Pathol . 160 , 389 – 401 ( 2002 ) . 137 . Toole , B . P . & Slomiany , M . G . Hyaluronan : a constitutive regulator of chemoresistance and malignancy in cancer cells . Semin . Cancer Biol . 18 , 244 – 250 ( 2008 ) . 138 . Yoshihara , S . et al . A hyaluronan synthase suppressor , 4 - methylumbelliferone , inhibits liver me tastasis of melanoma cells . FEBS Lett . 579 , 2722 – 2726 ( 2005 ) . 139 . Uchino , M . et al . Nuclear beta - catenin and CD44 upregulation characterize invasive cell popula tions in non - aggressive MCF - 7 breast cancer cells . BMC Cancer 10 , 414 ( 2010 ) . 140 . Takahashi , E . et al . Tumor necrosis factor - alpha regulates transforming growth factor - beta - depend ent epithelial - mesenchymal transition by promoting hyaluronan - CD44 - moesin interac tion . J . Biol . Chem . 285 , 4060 – 4073 ( 2010 ) . Elaborates in an in vivo model of fibrosis the con tribution of the HA – CD44 – moesin complex to EMT via TNF α . 141 . Acharya , P . S . et al . Fibroblast migration is mediated by CD44 - dependent TGF beta activation . J . Cell Sci . 121 , 1393 – 1402 ( 2008 ) . 142 . Allouche , M . , Charrad , R . S . , Bettaieb , A . , Greenland , C . , Grignon , C . & Smadja - Joffe , F . Liga tion of the CD44 adhesion molecule inhibits drug - induced apoptosis in human myeloid leuke mia cells . Blood 96 , 1187 – 1190 ( 2000 ) . 143 . Bates , R . C . , Edwards , N . S . , Burns , G . F . & Fisher , D . E . A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3 - kinase / Akt in colon carcinoma cells . Cancer Res . 61 , 5275 – 5283 ( 2001 ) . 144 . Fujita , Y . et al . CD44 signaling through focal adhesion kinase and its anti - apoptotic effect . FEBS Lett . 528 , 101 – 108 ( 2002 ) . 145 . Yu , Q . , Toole , B . P . & Stamenkovic , I . Induction of apoptosis of metastatic mammary carci noma cells in vivo by disruption of tumor cell surface CD44 function . J . Exp . Med . 186 , 1985 – 1996 ( 1997 ) . 146 . Marhaba , R . , Klingbeil , P . , Nuebel , T . , Nazarenko , I . , Buechler , M . W . & Zöller , M . CD44 and EpCAM : cancer - initiating cell markers . Curr . Mol . Med . 8 , 784 – 804 ( 2008 ) . 147 . Wang , S . J . & Bourguignon , L . Y . Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer . Arch . Otolaryngol . Head Neck Surg . 132 , 771 – 778 ( 2006 ) . 148 . Sherman , L . S . , Rizvi , T . A . , Karyala , S . & Ratner , N . CD44 enhances neuregulin signaling by Schwann cells . J . Cell Biol . 150 , 1071 – 1084 ( 2000 ) . 149 . Ghatak , S . , Misra , S . & Toole , B . P . Hyaluronan constitutively regulates ErbB2 phosphorylation and signaling complex formation in carcinoma cells . J . Biol . Chem . 280 , 8875 – 8883 ( 2005 ) . 150 . Misra , S . , Hascall , V . C . , Berger , F . G . , Markwald , R . R . & Ghatak , S . Hyaluronan , CD44 , and cyclooxygenase - 2 in colon cancer . Connect . Tissue Res . 49 , 219 – 224 ( 2008 ) . 151 . Orian - Rousseau , V . et al . Hepatocyte growth factor - induced Ras activation requires ERM pro teins linked to both CD44v6 and F - actin . Mol . Biol . Cell 18 , 76 – 83 ( 2007 ) . 152 . Matzke , A . et al . Haploinsufficiency of c - Met in cd44 - / - mice identifies a collaboration of CD44 and c - Met in vivo . Mol . Cell Biol . 27 , 8797 – 8806 ( 2007 ) . Demonstrates in a model of CD44 - deficient mice the functional importance of the crosstalk between CD44 and RTKs . 153 . Krause , D . S . & Van Etten , R . A . Tyrosine kinases as targets for cancer therapy . N . Engl . J . Med . 353 , 172 – 187 ( 2005 ) . 154 . Misra , S . , Toole , B . P . & Ghatak , S . Hyaluronan constitutively regulates activation of multiple receptor tyrosine kinases in epithelial and carcinoma cells . J . Biol . Chem . 281 , 34936 – 34941 ( 2006 ) . 155 . Lynch , C . C . , Vargo - Gogola , T . , Martin , M . D . , Fingleton , B . , Crawford , H . C . & Matrisian , L . M . Matrix metalloproteinase 7 mediates mammary epithelial cell tumorigenesis through the ErbB4 receptor . Cancer Res . 67 , 6760 – 6767 ( 2007 ) . 156 . Yu , Q . & Stamenkovic , I . Transforming growth factor - beta facilitates breast carcinoma metasta sis by promoting tumor cell survival . Clin . Exp . Metastasis 21 , 235 – 242 ( 2004 ) . 157 . Cooper , J . A . & Qian , H . A mechanism for SRC kinase - dependent signaling by noncatalytic re ceptors . Biochemistry 47 , 5681 – 5688 ( 2008 ) . 158 . Ingley , E . Src family kinases : Regulation of their activities , levels and identification of new path ways . Biochim . Biophys . Acta 1784 , 56 – 65 ( 2008 ) . 159 . Bates , R . C . , Elith , C . A . , Thorne , R . F . & Burns , G . F . Engagement of variant CD44 confers re sistance to anti - integrin antibody - mediated apoptosis in a colon carcinoma cell line . Cell Adhes . Commun . 6 , 21 – 38 ( 1998 ) . 160 . Katagiri , Y . U . et al . CD44 variants but not CD44s cooperate with beta1 - containing integrins to permit cells to bind to osteopontin independently of arginine - glycine - aspartic acid , thereby stimulating cell motility and chemotaxis . Cancer Res . 59 , 219 – 226 ( 1999 ) . 161 . Miletti - González , K . E . et al . The CD44 receptor interacts with P - glycoprotein to promote cell migration and invasion in cancer . Cancer Res . 65 , 6660 – 6667 ( 2005 ) . 162 . Misra , S . , Ghatak , S . & Toole , B . P . Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan , phosphoinositide 3 - kinase , and ErbB2 . J . Biol . Chem . 280 , 20310 – 20315 ( 2005 ) . 163 . Dean , M . , Fojo , T . & Bates , S . Tumour stem cells anddrug resistance . Nature Rev . Cancer 5 , 275 – 284 ( 2005 ) . 164 . Baumgartner , G . , Gomar - Höss , C . , Sakr , L . , Ulsperger , E . & Wogritsch , C . The impact of ex tracellular matrix on the chemoresistance of solid tumors - - experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy . Cancer Lett . 131 , 85 – 99 ( 1998 ) . 165 . Slomiany , M . G . et al . Abrogating drug resistance in malignant peripheral nerve sheath tumors by disrupting hyaluronan - CD44 interactions with small hyaluronan oligosaccharides . Cancer Res . 69 , 4992 – 4998 ( 2009 ) . 166 . Liu , C . M . , Chang , C . H . , Yu , C . H . , Hsu , C . C . & Huang , L . L . Hyaluronan substratum induces multidrug resistance in human mesenchymal stem cells via CD44 signaling . Cell Tissue Res . 336 , 465 – 475 ( 2009 ) . 167 . Xu , Y . , Stamenkovic , I . & Yu , Q . CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma . Cancer Res . 70 , 2455 – 2464 ( 2010 ) . 168 . Thiery , J . P . , Acloque , H . , Huang , R . Y . & Nieto , M . A . Epithelial - mesenchymal transitions in development and disease . Cell 139 , 871 – 890 ( 2009 ) . 169 . Mimeault , M . & Batra , S . K . New advances on critical implications of tumor - and metastasis - initi ating cells in cancer progression , treatment resistance and disease recurrence . Histol . Histopa thol . 25 , 1057 – 1073 ( 2010 ) . 170 . Guise , T . Examining the metastatic niche : targeting the microenvironment . Semin . Oncol . 37 Suppl 2 , S2 – 14 ( 2010 ) . 171 . Blum , B . & Benvenisty , N . The tumorigenicity of diploid and aneuploid human pluripotent stem cells . Cell Cycle 8 , 3822 – 3830 ( 2009 ) . 172 . Schatton , T . , Frank , N . Y . & Frank , M . H . Identification and targeting of cancer stem cells . Bioes says 31 , 1038 – 1049 ( 2009 ) . 173 . Godar , S . et al . Growth - inhibitory and tumor - suppressive functions of p53 depend on its repres sion of CD44 expression . Cell 134 , 62 – 73 ( 2008 ) . 174 . Akisik , E . , Bavbek , S . & Dalay , N . CD44 variant exons in leukemia and lymphoma . Pathol . On col . Res . 8 , 36 – 40 ( 2002 ) . 175 . Liebisch , P . et al . CD44v6 , a target for novel antibody treatment approaches , is frequently ex pressed in multiple myeloma and associated with deletion of chromosome arm 13q . Haema tologica 90 , 489 – 493 ( 2005 ) . 176 . Avin , E . , Haimovich , J . & Hollander , N . Anti - idiotype x anti - CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma . J . Immunol . 173 , 4736 – 4743 ( 2004 ) . One of few reports describing efficacy , selectivity and avoidance of side effects of bispecific anti bodies that target with both arms , one directed towards CD44 , the tumour cell . 177 . Yang , Z . F . et al . Significance of CD90 + cancer stem cells in human liver cancer . Cancer Cell 13 , 153 – 166 ( 2008 ) . 178 . Seiter , S . et al . Prevention of tumor metastasis formation by anti - variant CD44 . J . Exp . Med . 177 , 443 – 455 ( 1993 ) . 179 . Rupp , U . et al . Safety and pharmacokinetics of bivatuzumab mertansine in patients with CD44v6 - positive metastatic breast cancer : final re sults of a phase I study . Anticancer Drugs 18 , 477 – 485 ( 2007 ) . 180 . Tijink , B . M . et al . A phase I dose escalation study with anti - CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carci noma of the head and neck or esophagus . Clin . Cancer Res . 12 , 6064 – 6072 ( 2006 ) . 181 . Somasundaram , C . , Arch . , R . , Matzku , S . & Zöller , M . Development of a bispecific F ( ab’ ) 2 conjugate against the complement receptor CR3 of macro phages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage - mediated tumor cytotoxicity . Cancer Immunol . Immuno ther . 42 , 343 – 350 ( 1996 ) . 182 . Hibino , S . , Shibuya , M . , Engbring , J . A . , Mochizuki , M . , Nomizu , M . & Kleinman , H . K . Identification of an active site on the laminin al pha5 chain globular domain that binds to CD44 and inhibits malignancy . Cancer Res . 64 , 4810 – 4816 ( 2004 ) . 183 . Hibino , S . et al . Laminin alpha5 chain metastasis - and angiogenesis - inhibiting peptide blocks fibroblast growth factor 2 activity by binding to the heparan sulfate chains of CD44 . Cancer Res . 65 , 10494 – 10501 ( 2005 ) . 184 . Slomiany , M . G . , Dai , L . , Tolliver , L . B . , Grass , G . D . , Zeng , Y . & Toole , B . P . Inhibition of Functional Hyaluronan - CD44 Interactions in CD133 - posi tive Primary Human Ovarian Carcinoma Cells by Small Hyaluronan Oligosaccharides . Clin . Cancer Res . 15 , 7593 – 7601 ( 2009 ) . 185 . Ween , M . P . , Hummitzsch , K . , Rodgers , R . J . , Oehler , M . K . & Ricciardelli , C . Versican induces a pro - metastatic ovarian cancer cell behavior which can be inhibited by small hyaluronan oligosaccharides . Clin . Exp . Metastasis 28 , 113 – 125 ( 2011 ) . 186 . Golshani , R . , Lopez , L . , Estrella , V . , Kramer , M . , Iida , N . & Lokeshwar , V . B . Hyaluronic acid synthase - 1 expression regulates bladder cancer growth , invasion , and angiogenesis through CD44 . Cancer Res . 68 , 483 – 491 ( 2008 ) . 187 . De Stefano , I . et al . Hyaluronic acid - paclitaxel : effects of intraperitoneal administration against CD44 ( + ) human ovarian cancer xenografts . Cancer Chemo ther . Pharmacol . 2010 Sep 17 . [ Epub ahead of print ] . 188 . Rivkin , I . , Cohen , K . , Koffler , J . , Melikhov , D . , Peer , D . & Margalit , R . Paclitaxel - clusters coated with hyaluronan as selective tumor - targeted nanovec tors . Biomaterials 31 , 7106 – 7114 ( 2010 ) . 189 . Dhillon , J . , Astanehe , A . , Lee , C . , Fotovati , A . , Hu , K . & Dunn , S . E . The expression of activated Y - box binding protein - 1 serine 102 mediates trastuzu mab resistance in breast cancer cells by increasing CD44 + cells . Oncogene 29 , 6294 – 6300 ( 2010 ) . 190 . Gupta , P . B . et al . Identification of selective inhibitors of cancer stem cells by high - throughput screening . Cell 138 , 645 – 659 ( 2009 ) . 191 . So , J . Y . et al . A novel Gemini vitamin D analog represses the expression of a stem cell marker CD44 in breast cancer . Mol . Pharmacol . 79 , 360 – 367 ( 2011 ) . 192 . Anido , J . et al . TGF - β Receptor Inhibitors Target the CD44 ( high ) / Id1 ( high ) Glioma - Initiating Cell Population in Human Glioblastoma . Cancer Cell 18 , 655 – 668 ( 2010 ) . Acknowledgements The author would like to cordially thank ( former ) people of her laboratory for cited work , and R . Marhaba and K . Malinowska for helpful comments . The author’s laboratory is supported by the German Research Foundation , The German Cancer Research Foundation and the National Cancer Centre , Hei delberg / Mannheim . Competing interests statement The author declares no competing financial interests . FURTHER INFORMATION Margot Zöller’s homepage : http : / / www . klinikum . uni - heidelberg . de / Tumorzellbiologie . 111908 . 0 . html SUPPLEMENTARY INFORMATION See online article : S1 ( table ) | S2 ( table ) | S3 ( figure ) ALL LINKS ARE ACTIVE IN THE ONLINE PDF R E V I E W S NATURE REVIEWS | CANCER VOLUME 11 | APRIL 2011 | 267 © 2011 Macmillan Publishers Limited . All rights reserved